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Chapter 1  -  Introduction
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In his essay ‘On Chorea’, George Huntington (1850 - 1916) described three disease  characte- 
ristics of what was since then called Huntington’s chorea: the hereditary nature, the  tendency 
to  insanity and suicidal behavior, and the manifestation of the illness at adult age.1 Clearly, 
he was already aware that next to the observable motor symptoms, patients also suffer from 
 psychiatric disorders.
History
In the early twentieth century, the Dutch psychiatrist Gerbrandus Jelgersma (1859 - 1942) 
 portrayed ‘chorea hereditaria’ as an organic brain disease with severe psychiatric symptoms that 
occurred in specific families. In his ‘Leerboek der Psychiatrie’, he discussed all kinds of  psychiatric 
symptoms which he had seen in patients with this disease: melancholia,  dysphoria,  irritability, 
anxiety, delusional thoughts, indifference, ignorant behavior, and at the end  dementia.2 For a 
long period, patients with Huntington’s disease were hospitalized mainly in psychiatric  hospitals, 
because of their severe psychiatric symptoms.
In 1983, the localization of a DNA polymorphism linked with the transmission of Huntington’s 
disease was reported.3 Genetic linkage analysis to assess the risk of developing the disease with 
95% accuracy became available in 1986. Finally, the causal genetic mutation of Huntington’s 
disease was discovered in 1993.4 Since this discovery, predictive testing with a theoretical 100% 
accuracy became available. Although predictive testing is widely available in the Netherlands, 
only 25% of all persons at risk choose to be tested.
Clinical features
Huntington’s disease is characterized by a triad of psychiatric, motor, and cognitive symptoms.5 
These symptoms commonly co-occur, though in clinical practice patients are typically only 
 diagnosed with Huntington’s disease once motor symptoms appear.
Psychiatric symptoms
The occurrence of psychiatric symptoms can be the first sign of Huntington’s disease.6 A  subtle, 
though progressive, personality change may herald the onset of the disease.  Psychopathology 
in Huntington’s disease includes psychiatric disorders such as depression, as well as 
 neuropsychiatric behavioral problems such as apathy and impulsivity.7,8
Reported prevalences of different psychiatric disorders and behavioral problems vary widely, 
depending on the criteria used and disease stage examined. Also, major differences exist in 
applied  measurements, study design being retrospective or prospective, sample sizes, use of 
 informants, and the analyzed time period. Furthermore, assessment of psychopathology in 
Huntington’s disease is complicated due to co-morbid somatic and cognitive disturbances, and 
diminished disease awareness.9,10
Motor symptoms
Early motor signs of Huntington’s disease include the gradual onset of clumsiness and  balance 
difficulties, that might be unrecognized by the patient. Movement disorders are usually  slowly 
progressive. The most prominent movement disorder in Huntington’s disease is  chorea, 
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 characterized by unwanted, jerky movements of head, trunk, and limbs. The gait is poorly 
 coordinated and mimics a dance, and was therefore called chorea (Greek: to dance). As the 
disease progresses, chorea may become more pronounced, but other movement disorders also 
occur, such as dystonia, rigidity, bradykinesia, hypokinesia, and postural instability.  Swallowing 
and speech dysfunction develop during the course of the illness and ultimately lead to  dysphagia 
and an inability to communicate. In the most advanced stage of the disease, almost all patients 
are totally dependent on full time skilled nursing.
Cognitive symptoms
Cognitive disorders are also prevalent in Huntington’s disease, and can occur before motor 
symptoms are present.11 Severity and progression of cognitive disorders vary considerably, 
but many patients develop severe subcortical dementia in advanced disease stage.12  Cognitive 
 assessment typically shows deficits predominantly in frontal executive functions, including 
 abstract thinking, problem solving, attention, mental set shifting, sequencing, and mental 
 generation of information.13 A loss of cognitive speed and flexibility may not be acknowledged 
as a disease symptom, and may subsequently cause problems in social relations. 
Inheritance
Huntington’s disease is a neurodegenerative disorder with an autosomal dominant pattern of 
inheritance, resulting in an a-priori 50% risk of developing the disease for every child when one 
of the parents is affected.14 The causal genetic mutation of Huntington’s disease is localized on 
the short arm of chromosome 4 (4p16.3). This genetic modification is an expanded cytosine-
adenine-guanine (CAG) trinucleotide repeat coding for the protein huntingtin. A CAG expansion 
of 36 repeats or more is associated with Huntington’s disease, though a repeat between 36 to 
39 repeats has a reduced penetrance and may not in all cases result in the clinical phenotype. 
Higher repeat length is associated with a younger age of onset, but the repeat length seems 
to determine the age of onset only partially (about 60%).15 Previous studies have shown that 
parental age of onset is an additional predictor of the age of onset, and presumably reflects 
genetic and/or environmental influences.16
Epidemiology
The prevalence of Huntington’s disease varies widely, depending on the geographic region; in 
Europe and Northern-America the prevalence is approximately 7 - 9 per 100,000 inhabitants.17 
The total number of symptomatic patients in The Netherlands is about 1,200 - 1,500.18 Another 
6,000 to 9,000 persons have a 50% risk of developing Huntington’s disease.
The mean age of onset is difficult to estimate accurately, because onset symptoms differ widely. 
The age of onset of motor symptoms is usually between 30 and 50 years (range 2 - 80 years), but 
many patients experience psychiatric symptoms before the presence of motor symptoms. The 
mean duration of illness is approximately 16 years.19
Neuropathology
So far, the neuropathology of Huntington’s disease is not understood. A regional selectivity of atro-
phy and neuronal loss in the caudate nucleus and putamen of the striatum is common, but other 
regions may also be affected. Some neurons contain intranuclear inclusions that are  characteristic 
for Huntington’s disease, though their role in the pathogenesis of the disease is not known.20
Disease stage
The period before the onset of symptoms is called the presymptomatic or premanifest period. 
The appearance of one of the characteristic motor, psychiatric or cognitive symptoms is the start 
of the disease, and – if one has not been tested – reveals the carriership of the disease.
The progression of the disease can be defined by the duration of illness, the presence and 
 severity of symptoms, or the level of functional impairment. So far, no objective criterion for 
disease stage (e.g., atrophy of the striatum) is available. In this study, a conservative approach 
is applied to differentiate presymptomatic and symptomatic mutation carriers. A neurologist 
expressed his level of confidence that the presence of motor symptoms in a study subject is a 
sign of clinically manifest Huntington’s disease. This confidence level is an item of the widely 
used motor section of the Unified Huntington’s Disease Rating Scale (UHDRS), and ranges from 0 
to 4.5 All mutation carriers with confidence level score 0 (normal) or score 1 (nonspecific motor 
abnormalities; < 50% confidence) were classified as presymptomatic. The remaining mutation 
carriers with score 2 (motor abnormalities that may be signs of Huntington’s disease; 50% - 89% 
confidence), score 3 (likely signs of Huntington’s disease; 90% - 98% confidence), or score 4 
(unequivocal signs of Huntington’s disease; ≥ 99% confidence) were considered symptomatic.
Focus of this thesis: Psychopathology in Huntington’s disease
During the course of Huntington’s disease, most patients will develop psychiatric disorders or 
behavioral problems that have an important negative impact on their quality of life and add 
 greatly to their suffering and the burden of caregivers. Therefore, it is important to gain insight in 
the prevalence and characteristics of psychopathology. However, diagnosis of  psychopathology 
in Huntington’s disease is complicated by the presence of co-morbid disorders, overlapping 
symptoms, and a diminished insight. Apathy, for example, may be a symptom of depression, but 
can also occur independently as a syndrome in its own right, and is more often a complain of 
caregivers rather than of patients themselves.
An important previous study describing psychopathology in Huntington’s disease showed 
that behavioral problems can be divided in three symptom clusters: depression, apathy and 
 irritability.8 This study also showed that psychopathology in Huntington’s disease may have 
disease specific features, that fluctuate during the progression of the disease. 
No association has been found between psychopathology in Huntington’s disease and the 
 expanded CAG repeat length.21 Furthermore, it is unknown to what extend alternative 
 genetic, biologic or environmental factors contribute to the presence of psychopathology. For 
example, exposure to potential stressful life circumstances, e.g., growing up in stressful family 
 circumstances and being at risk for Huntington’s disease, can result in an increase of stress 
 hormones by hyperactivity of the hypothalamic-pituitary adrenal axis. This increased level of 
stress hormones may be one of the biological factors that contribute to the manifestation of the 
first subtle symptoms of Huntington’s disease, including psychiatric symptoms.22
16
Chapter 1  -  Introduction
17
Aims of the study
Primary aim
The primary aim of this thesis was to assess the prevalence of both formal psychiatric disorders 
and behavioral problems. We assumed that members of families with Huntington’s disease, 
 regardless of their genetic status, would all show an increased prevalence of psychiatric 
 disorders and behavioral problems compared to the general population.
We started with a review of the literature, that was used to guide the design of the study, to 
identify psychiatric disorders and behavioral problems in Huntington’s disease, and to  obtain a 
set of reference data (Chapter 2). Since differences in study population and measurement tools 
used, resulted in widely variable prevalences, we assessed psychopathology both  conservatively 
with diagnostic criteria according to the Diagnostic and Statistical Manual of mental disorders, 
Version IV (DSM-IV) (Chapter 3), and with the recently developed Problem Behaviors  Assessment 
scale (Chapter 4).
Secondary aims
We hypothesized that measurement tools using caregiver information are more appropriate 
to detect psychopathology in advanced stage of Huntington’s disease. Therefore, we assessed 
the concurrent validity of two rating scales using caregiver information, that were specifically 
designed for the assessment of psychopathology in Huntington’s disease, in comparison with a 
categorical assessment of psychiatric disorders as defined by criteria of the DSM-IV (Chapter 5).
Since apathy showed to be a frequent neuropsychiatric symptom in Huntington’s disease, we 
aimed to assess the prevalence as well as the sociodemographic, clinical and neuropsychiatric 
correlates of apathy in Huntington’s disease (Chapter 6). Furthermore, we aimed to  investigate 
the function of the hypothalamic-pituitary-adrenal axis as one of the potential biological 
markers in relation to symptoms of Huntington’s disease in an explorative way (Chapter 7).
In the general discussion the results of this thesis are put into a wider perspective together with 
recommendations for future research (Chapter 8). 
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Huntington’s disease is characterized by motor, cognitive, and neuropsychiatric symptoms. 
This study reviews original research on psychopathology in Huntington’s disease that uses 
 standardized instruments in verified mutation carriers. Frequently reported  neuropsychiatric 
symptoms are depressed mood, anxiety, irritability, and apathy, with prevalences of 33% to 
76%. Obsessive-compulsive symptoms and psychosis occur less often with prevalences of 
10% to 52% and 3% to 11%, respectively. Available research provides little insight into the 
true  prevalences of psychopathology in Huntington’s disease due to small sample sizes, use 
of  different  methodologies, and lack of comparison groups. Future research requires larger 
 cohorts stratified to disease stage, consistent methodologies, and adequate comparison groups. 
Introduction
Huntington’s disease, a progressive autosomal-dominant neurodegenerative disorder, is 
 traditionally characterized by choreiform motor disturbances. In addition to motor symptoms 
and cognitive deterioration, neuropsychiatric symptoms comprise part of the Huntington’s 
disease phenotype.1-3 The genetic defect underlying Huntington’s disease is an unstable and 
expanded CAG repeat in exon 1 of gene IT15 on the short arm of chromosome 4, which is 
 expressed as a mutant polyglutamic tract in the protein huntingtin (Htt).4-7 The mechanisms by 
which the mutant Htt protein induces a cascade of cellular changes, leading to cell  dysfunction 
and degeneration, have not yet been fully elucidated. Modulation of genetic functioning through 
the IT15 gene, neuronal death in relation to intranuclear inclusions of aggregated mutant Htt, 
and progressive cerebral degeneration starting in the caudate nucleus and the putamen may all 
be part of the pathophysiology of Huntington’s disease.8-11
Estimated rates for lifetime prevalence of psychiatric disorders among Huntington’s disease 
 patients vary widely between 33% and 76%.3,10 The investigated neuropsychiatric symptoms 
 include depressed mood, anxiety, irritability, apathy, obsessions and compulsions, and  psychosis. 
This variation in prevalences can be explained by the use of different assessment methods with 
varying definitions of neuropsychiatric phenomena. No follow-up studies covering a longer 
 period have been performed.
For many patients and their relatives, these neuropsychiatric symptoms constitute the most 
distressing aspect of Huntington’s disease and often constitute reason for hospitalization.12 
Whereas severity of motor and cognitive dysfunction is only moderately related to the  severity 
of functional decline, behavioral symptoms and psychiatric disorders seem to have a more 
 severe negative effect on daily functioning.13 Previous findings have suggested, although 
 inconclusively, that psychopathology as well as cognitive dysfunction may precede the onset of 
motor symptoms in many patients.14-16
To get more insight into the occurrence and prevalence of behavioral problems and  psychiatric 
disorders in Huntington’s disease, we review the literature on psychopathology in verified 
 Huntington’s disease mutation carriers, with particular reference to its relationship with disease 
onset and progression, as well as possible underlying neuropathological pathways. We conclude 
with several recommendations for future research. 
Data sources
We searched two literature databases, Embase and PubMed, for prevalence of psychopatho-
logy in Huntington’s disease. We used a variety of search terms, all synonyms for Huntington’s 
disease and various (neuro)psychiatric phenomena. Where possible, these were mapped 
onto the following standard database terms (subject headings/MeSH terms): ‘Huntington’s 
disease’, ‘Huntington’s chorea’, ‘mood disorder(s)’, ‘affect’, ‘anxiety disorder(s)’, ‘obsessive be-
havior’, ‘compulsive behavior’, ‘schizophrenia and disorders with psychotic features’, ‘psychosis’, 
‘thought disorder’, ‘dissociative disorder(s)’, ‘neurotic disorder(s)’, ‘neurosis’, ‘impulse control 
disorder(s)’, ‘impulsive behavior’, ‘irritable mood’, ‘apathy’, ‘behavioral symptoms’, ‘behavior 
disorder(s)’, and ‘personality disorder(s)’. Animal studies and studies on pathophysiology were 
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excluded and the language was limited to English. The references of the resulting articles were 
hand searched for further relevant literature. This search resulted in 134 articles, including 59 
articles describing original research, 29 review articles, 25 articles on psychopharmacological 
treatment, 19 case reports/series, and two editorials.
In order to estimate the cumulative prevalences and 95% confidence intervals (CI) of psycho-
pathological phenomena, the 59 articles on original research were further selected for meeting 
the following conclusive set of criteria:
1) The study was original and measured the prevalence of psychopathology in a motor 
 symptomatic Huntington’s disease population.
2) The study applied standardized instruments with defined validity and reliability.
3) The study used samples with verified CAG repeat expansions, which implied publication after 
 1993 when the Huntington’s disease mutation was identified.
Results
A total of seven original articles met the final set of strict criteria (Table 1). The other 52  articles 
were excluded for the following reasons: 22 articles did not cover research on the  prevalence 
of psychopathology; one article only concerned alcohol abuse; one exclusively concerned 
sexual abuse; and seven others concerned suicide/suicidal behavior. In three studies, solely 
pre-motor symptomatic subjects were included, and in five studies subjects were offspring of 
 Huntington’s disease mutation carriers and had not been genetically verified. One article was 
excluded  because only patients in a nursing home were examined. Of the remaining articles, 
10 did not mention standardized instruments with defined validity and reliability and, in two 
articles, subjects were clinically suspected for Huntington’s disease, but CAG repeat numbers 
were not verified. The remaining seven articles employed the following instruments for the 
assessment of behavioral and psychiatric symptoms: the Neuropsychiatric Inventory (NPI),17,18 
the Structured Clinical Interview for the DSM-III (SCID),19 the behavioral section of the Unified 
Huntington Disease Rating Scale (UHDRS),20,21 the Yale-Brown Obsessive Compulsive  Symptom 
(Y-BOCS) scale,22 and the more recently developed Problem Behavior Assessment Scale for 
 Huntington’s Disease (PBA),23 which rates severity and frequency of behavioral problems in 
Huntington’s disease.
A broad range of symptoms portraying a chronically progressive course and fluctuating  clinical 
picture are reported as neuropsychiatric features of Huntington’s disease. These  neuropsychiatric 
phenomena are de noted by an array of terms, for example: behavioral problems or symptoms, 
personality changes, and psychiatric problems or disorders. The  characteristic behavioral  changes 
in early stage Huntington’s disease, including depression, irritability, mental  inflexibility, and 
apathy, have in earlier days been described as ‘choreopathy’.24 We have limited our  subsequent 
analyses to the most frequently reported symptoms of depressed mood, anxiety, irritability, 
apathy, obsessive and compulsive symptoms, and psychosis. Originally, we intended to estimate 
the cumulative prevalences of the different neuropsychiatric phenomena. In spite of our strict 
inclusion criteria, however, large inconsistencies in methodology remained. This would lead 
to neither reliable nor valid results; studies used different assessment methods with strongly 
 varying definitions of neuropsychiatric phenomena. For example, the definition of depression 
is much stricter according to the SCID than to the UHDRS.25,26 Also, out of two studies using the 
same neuropsychiatric assessment measure in populations of comparable disease duration and 
cognitive function, one study17 consistently reported lower prevalences than the other.18 This 
suggests a strong bias. Furthermore, the criteria for the onset of Huntington’s disease are not 
always given, the comparability of reported disease durations is highly questionable, and finally, 
not all populations are well-described. We therefore assumed them to be outpatients unless 
otherwise noted.
Table 1. Overview of included articles on psychopathology in Huntington’s disease
Year Author n Disease duration* Measure Symptoms
2001 Anderson et al.22 27 Unknown Y-BOCS  Obsessive and/or compulsive symptoms 
2001 Craufurd et al.23 78 9 ± 5 PBA-HD  Apathy, irritability, depressed mood,  
      anxiety, obsessive and/or compulsive  
      symptoms, psychotic symptoms 
2001 Kulisevsky et al.17 29 5.6 ± SEM 1.6 NPI Apathy, irritability, depressed mood,  
      anxiety, psychotic symptoms 
2001 Murgod et al.20 26 5.5 ± 3.9 UHDRS  Apathy, irritability, depressed mood,  
      anxiety, obsessive and/or compulsive  
      symptoms, psychotic symptoms 
2001 Paulsen et al.18 52 4.7 ± 4.4 NPI  Apathy, irritability, depressed mood,  
      anxiety, psychotic symptoms 
2002 Leroi et al.19 21 12.0 ± 6.6 SCID  Depressive disorder
2005 Paulsen et al.21 2835 7.6 ± 6.0 UHDRS  Depressed mood, anxiety 
* Disease duration in years (mean ± standard deviation; SEM: Standard Error of the Mean)
Y-BOCS: Yale-Brown Obsessive Compulsive Scale; PBA-HD: Problem Behaviour Assessment for Huntington’s disease; NPI: Neuropsychiatric In-
ventory; UHDRS: Unified Huntington Disease Rating Scale; SCID: Structured Clinical Interview for DSM
Depressed mood
Six original studies investigate the prevalence of depressed mood in motor symptomatic 
 patients.17-21,23 Though two studies used the UHDRS to assess the prevalence of ‘low mood’,20,21 
and two others used the NPI,17,18 results vary strongly, from 33% to 69% (Figure 1). The only 
study using formal DSM criteria reports a prevalence of 43% for mood disorders: 29% for major 
depression and 14% for non-major depression.19
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Five studies assess the prevalence of anxiety (Figure 2).17,18,20,21,23 The lowest prevalence (34%) 
was reported with the NPI.17 The prevalence almost doubled (61%) in a small study, using the 
UHDRS, in 26 Huntington’s disease patients at their first hospital visit because of manifesting 
motor symptoms.20
Irritability
Irritability, varying in description from ‘difficult to get along with’ to ‘aggression’, is characterized 
by a reduction in control over temper that may result in verbal or behavioral outbursts.27 In four 
original studies that assessed irritability as a separate behavioral phenomenon in Huntington’s 
disease, prevalences varied between 38% and 73% (Figure 3).17,18,20,23
Apathy
Apathy, characterized by reduced energy and activity, lack of drive, and impaired performance 
of everyday tasks, may be a separate clinical entity distinct from depression, especially in neuro-
psychiatric disorders.28,29 In three original studies, prevalences of apathy in Huntington’s disease 
patients varied from 34% to 76% (Figure 4).17,18,23 Using the PBA, a cluster of symptoms reflecting 
apathy syndrome was found, with ‘loss of energy’ (88%), ‘impaired performance of everyday 
life’ (76%), and ‘lack of initiative’ (76%) as the most prevalent behavioral abnormalities.23
28




Obsessive and compulsive symptoms
The three studies investigating obsessive or compulsive behavior (Figure 5) reported  prevalences 
of 10% to 52%.20,22,23 Out of 27 Huntington’s disease patients visiting an outpatient clinic, 52% 
scored either on compulsions or obsessions on the Y-BOCS.22 The prevalence of  obsessive 
symptoms was twice that of compulsive symptoms, while all patients with compulsive symptoms 
also had obsessive symptoms. Only two out of the 27 patients fulfilled formal DSM criteria for 
obsessive compulsive disorder. The two remaining studies reported lower  prevalences in larger 
study populations.20,23
Psychotic symptoms
Prevalences of psychotic symptoms varied between 3% and 11% in four studies.17,18,20,23 Because 
of small sample sizes, three of the four studies report 95% confidence intervals that include a 
prevalence of 0% (Figure 6).17,20,23
Discussion
These results confirm that behavioral problems and psychiatric disorders are major constituents 
of the clinical spectrum of Huntington’s disease. This is an important finding because these 
neuropsychiatric symptoms have a substantial impact on daily functioning,12 possibly even more 
so than motor and cognitive dysfunctions.13 Nevertheless, more and better designed studies are 
necessary.
The studies up to date use a variety of assessment methods in Huntington’s disease populations 
of different disease stages. This ensures that their results are impossible to compare and that 
reliable prevalence estimates cannot be made. Definitions of neuropsychiatric phenomena are 
often unclear, and differences in definition can strongly influence the prevalences found. For 
example, in the UHDRS only one item refers to ‘low mood’, whereas the SCID uses the stringent 
DSM criteria for depression. These different methodologies limit the generalizability of the re-
ported findings, which is further impaired by small sample sizes. Importantly, none of the seven 
studies found used a representative comparison group and, to our knowledge, no follow-up 
studies have been performed to relate the incidence of behavioral problems and psychiatric 
disorders to disease onset and disease progression.
Psychopathology
The prevalence of depressed mood in Huntington’s disease, varying from 33% to 69%, may be 
comparable to that of anxiety, irritability, and apathy. The development of depressive symptoms 
in Huntington’s disease could be a direct result of cerebral degeneration, for which several 
 neuropathological mechanisms have been proposed proposed.30,31 Depression could,  however, 
equally well be a psychological reaction to being at risk for Huntington’s disease,  having grown 
up in an insecure and harmful environment, and/or the awareness of disease onset.
Many studies have found that depressive symptoms precede the onset of motor symptoms,32-34 
but no relation between the occurrence of depressive symptoms and disease duration has so 
far been reported.35 Depression may, however, negatively correlate to cognitive decline,23 which 
is possibly the result of concurrent decreasing illness awareness. Anxiety has not been a main 
research interest in patients with Huntington’s disease. Nevertheless, ‘worrying’, which could be 
part of a generalized anxiety disorder (GAD), is often  reported in Huntington’s disease patients, 
although it is mostly limited to worries about Huntington’s disease.36 Since no studies were 
found that systematically investigate the prevalences of  different anxiety disorders, this should 
be an important focus for future research.
Irritability without a prior history of short temper occurs in most Huntington’s disease  patients, 
and seems to precede motor symptoms in mutation carriers.37-39 A tendency for irritability 
 occurring more frequently in late stage patients whose neurological symptoms have been 
 present for 6 to 11 years has also been described.23 This is confirmed by a cross-sectional 
 observational study of 27 nursing home residents with Huntington’s disease (disease duration 7 
to 11 years), which reports aggression in one-third of all patients over a 3-day period.40
We contend that increasing degeneration of the striatum and the orbito-frontal- subcortical 
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 circuit in Huntington’s disease contributes to the development of socially inappropriate 
 behavior, which initially may be manifested as subtle irritability and, in late-stage Huntington’s 
disease, as aggressive behavior.41
Of all neuropsychiatric symptoms only apathy consistently appears to be positively related to 
disease progression.23,42,43 Apathy is also strongly related to the decline of everyday  functioning 
and, once present, tends to persist or worsen.12 Damage to structures of the  anterior 
 cingulate-subcortical circuit has in particular been associated with motivational disorders, 
 including apathy,41 which may also be the case in Huntington’s disease.44
The occurrence of obsessive and compulsive symptoms in Huntington’s disease is of  particular 
 interest because obsessive-compulsive disorder and Huntington’s disease possibly share 
a  similar neuropathology of the basal ganglia and (orbito)frontostriatal circuits.45,46 Many 
 Huntington’s disease mutation carriers show personality changes with mental inflexibility in 
early stages,23 possibly heralding future obsessive and compulsive symptoms. Though in certain 
families  obsessive and compulsive symptoms have shown an early phenotype of Huntington’s 
disease,45 they are not often identified as a manifestation of Huntington’s disease.47
Psychotic symptoms usually occur when movement symptoms are already clearly manifest. This 
could explain why in earlier days, when Huntington’s disease was diagnosed at a later disease 
stage, psychosis was usually described as the main psychiatric feature of  Huntington’s disease.48 
Even so, Huntington’s disease patients were often misdiagnosed with dementia  praecox 
or  schizophrenia until the first half of the 20th century. Nowadays, rather low  prevalences 
(3% to 11%) of psychotic symptoms are reported, which is most probably due to earlier and 
better  diagnoses of Huntington’s disease and a shift in research from inpatient to outpatient 
 populations.
Recommendations for future research
The causal pathways leading to psychopathology in Huntington’s disease are unclear and should 
receive priority on the research agenda. Since Huntington’s disease families with  multiple 
 cases of schizophrenia and schizophreniform symptoms have been described,49,50 as well as 
 families with obsessive-compulsive disorders,45 and families with a high occurrence of  affective 
 syndromes in both mutation carriers and non-carriers,51 it is highly probable that other genes 
than the Huntington’s disease gene itself, as well as environmental factors, play a role in the 
 development of psychopathology in Huntington’s disease.52 Previous findings indeed suggest 
that both neuropathology and environmental stress contribute to the occurrence of neuro-
psychiatric phenomena in Huntington’s disease: a case series among 37 Huntington’s disease 
patients and 167 relatives reported significantly more psychiatric admissions and diagnoses 
in patients than in their relatives.53 Thus at least some psychopathology will be due to the 
 etiology of Huntington’s disease, though not solely the Huntington’s disease mutation. Since 
the same study showed that relatives of Huntington’s disease patients also had more psychiatric 
d iagnoses and admissions than the general population, stressors such as growing up with an 
 affected parent and with the uncertainty about one’s own disease status are also likely causes 
of psychopathology in Huntington’s disease.
To correct for environmental stress, prevalences of psychopathology in Huntington’s disease 
should be compared to healthy family members, particularly siblings of patients who do not  carry 
the Huntington’s disease mutation, since they share the same psychosocial family  background 
as mutation carriers. There is need for prospective research covering all  different stages of 
 Huntington’s disease with the use of such a comparison group, just as has been  carried out 
before in pre-motor symptomatic mutation carriers.37,39 Though this comparison group cannot 
correct for all potential biases affecting research in this difficult population (e.g.,  self-selection 
for genetic testing and difficulties with the staging of disease progression), use of the proposed 
comparison group will significantly increase the validity and interpretability of the test results. 
Also, a comparison of psychopathology in Huntington’s disease with other  neurodegenerative 
disorders, such as Parkinson’s disease, could increase our understanding of the pathological 
 mechanisms that affect the brain and behaviors of these patients.17,46,54  Nevertheless, such 
a comparison should be explorative in nature as neither Huntington’s disease patients nor 
 patients with Parkinson’s seem an adequate comparison group to the other.
As the Huntington’s disease mutation does not have a full penetrance for developing specific 
behavioral problems or psychiatric disorders, research should also focus on the  contribution 
of other biological factors, as well as environmental factors, to the behavioral phenotype of 
 Huntington’s disease. Identification of endophenotypes, which do not depend on what is 
 obvious to the unaided eye, could help to resolve questions about etiological models.55 Such 
an endophenotype-based approach has the potential to assist in the genetic dissection of 
 psychopathology. These endophenotypes should be researched on the level of neurobiology, 
neuropsychology, and neuroradiology. An example of a possible neurobiological endopheno-
type is disturbance of the hypothalamic pituitary adrenal (HPA) axis functioning with hyper-
cortisolism; the stress hormone cortisol plays a major role in psychiatric disorders,  particularly 
depressive disorders that have a high prevalence in Huntington’s disease. Disturbances in 
HPA-axis functioning have already been found in Huntington’s disease patients but have not 
yet been linked to behavioral or psychiatric morbidity in Huntington’s disease.56,57 Another pos-
sible endophenotype is dysfunction of the immunesystem,58 with altered secretion of cytokines. 
These have also been related to the presence of depression.59 Vulnerability to psychopathology 
may be determined by genetic polymorphisms of the HPA-axis and the immune system, which 
is another important area of research in Huntington’s disease.60
All future research should improve upon current methodologies. Some potential sources of 
 current variation in test results, such as low incidence of Huntington’s disease with resulting small 
sample sizes and self-selection for testing and research, are difficult to avoid;  researchers should 
be aware of this. Other sources of variety, mainly differences in methodology, can be eliminated 
if consensus on terminology and staging methods, as well as standardization of  instruments are 
achieved. This is a necessary requirement for the comparability and  generalizability of  results. 
We propose that DSM criteria are used as the gold standard for psychiatric diagnosis, and 
standardized instruments for other neuropsychiatric symptoms, such as apathy and irritability.
For disease progression, we propose the motor section of the UHDRS. Although the motor  score 
is not perfectly correlated with disease progression, a functional assessment with the Total 
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Functional Capacity scale of the UHDRS,61 which is related to disease progression, is not a good 
tool for this kind of research, as it is directly influenced by psychopathology.12,62 Because the 
onset of Huntington’s disease is so gradual, disease duration is also not an adequate  measure, 
and motor assessment is therefore the most objective, reliable, and comparable method of 
disease staging for research.
Research should lead to an increased understanding and recognition of psychopathology in 
Huntington’s disease and its causes. This is essential for adequate treatment of those symptoms 
that could improve the overall functioning and quality of life of the Huntington’s disease patient 
and his or her direct environment. 
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Abstract
Objective: To investigate the prevalences of formal DSM-IV diagnoses in pre-motor  symptomatic 
and motor-symptomatic mutation carriers at different stages of Huntington’s disease compared 
to a control group of first-degree non-carriers relatives and the general population.
Method: Between May 2004 and August 2006, 154 verified mutation carriers and 56 verified 
non-carriers were recruited from the outpatient clinics of the Neurology and Clinical Genetics 
departments of Leiden University Medical Center and from a regional nursing home. To assess 
the 12-month prevalences of DSM-IV diagnoses, the sections for depression, mania, anxiety, 
obsessive-compulsive disorder, and psychosis/schizophrenia of the Composite International 
 Diagnostic Interview were used. Prevalences in the Dutch general population were extracted 
from the Netherlands Mental Health Survey and Incidence Study (NEMESIS).
Results: Both presymptomatic and symptomatic mutation carriers portrayed significantly more 
major depressive disorder (p = 0.001 and p < 0.001, respectively) and obsessive-compulsive 
 disorder (p = 0.003 and p = 0.01, respectively) than the general population. Symptomatic 
 mutation carriers also showed an increased prevalence (p = 0.01) of non-affective psychosis. 
Psychiatric disorders were more prevalent, although not significantly (p = 0.06), in mutation 
 carriers compared to first-degree relatives who were non-carriers. Non-carriers did not differ 
from the general population.
Conclusion: Psychiatric disorders occur frequently in Huntington’s disease, often before  motor 
symptoms appear. In addition, first-degree non-carriers relatives do not show more  psychiatric 
disorders compared to the general population, although they grew up in comparable,  potentially 
stressful circumstances. Taking these findings together, psychopathology in Huntington’s disease 
seems predominantly due to cerebral degeneration rather than to shared environmental risk 
factors. 
Introduction
Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disorder resulting 
from an expanded trinucleotide CAG repeat, which codes for a polyglutamine in the IT15 gene 
on  chromosome 4p16.3.1 The pathogenesis in relation to the CAG repeat expansion has not yet 
been elucidated, but several processes have been suggested.2 The mean age at onset is between 
30 and 50 years. The first signs consist of involuntary movements (chorea,  hypokinesia),  cognitive 
deterioration, behavioral problems, and psychiatric disorders. There is no curative  treatment 
for Huntington’s disease. Since 1993, presymptomatic gene testing has been  available.1 In The 
 Netherlands, about 1200 to 1500 patients have symptoms of  Huntington’s disease, 6000 to 
9000 persons are at 50% risk for Huntington’s disease, and every year approximately 60 persons 
at 50% risk are tested gene-positive.
Psychiatric disorders may occur in all motor symptomatic stages of Huntington’s disease and 
can also predate the onset of motor symptoms.3-5 These disorders have an important negative 
impact on quality of life, add greatly to the suffering of patients and the burden of caregivers, 
increase the risk of institutionalization,6,7 and may account for increased mortality and risk of 
suicide.8,9 Little is known about true prevalences of psychiatric disorders in verified Huntington’s 
disease mutation carriers. This lack of information is due to small sample sizes, use of  different 
methodologies, and lack of adequate control groups.10 We therefore aimed to investigate the 
12-month prevalences of formally diagnosed psychiatric disorders in verified  Huntington’s 
disease mutation carriers compared to a control group of verified first-degree non-carriers 
 relatives and the general population. 
Since being at risk for this incurable disorder and having been raised in an Huntington’s disease 
family is likely to have an impact on mental well-being,11,12 we assumed that Huntington’s disease 
family members, regardless of their genetic status, would all show increased  prevalences of 
 psychiatric disorders compared to the general population. 
Methods
Subjects
Between May 2004 and August 2006, 361 subjects were recruited from 4 sources (Figure 1). 
First, an invitational letter was sent to 174 subjects who had attended the Department of 
 Clinical Genetics of Leiden University Medical Center between 1999 and 2004 for Huntington’s 
disease mutation analysis. Leiden University Medical Center is a Dutch teaching hospital and 
a  national reference center for Huntington’s disease. Next to verified Huntington’s disease 
 mutation  carriers, verified first-degree non-carriers relatives — with an a priori 50% risk for 
Huntington’s disease — were enrolled as a comparison group to control for environmental 
factors such as  growing up with an ill parent in potentially harmful family circumstances, the 
knowledge of being at risk for Huntington’s disease, and participating in the predictive testing 
procedure.  Second, an invitational letter was sent to all Huntington’s disease patients (n = 119) 
currently  attending the outpatient clinic of the Department of Neurology of Leiden University 
Medical Center. Third, one nursing home (Overduin in Katwijk) in the area of Leiden with a 
 specialized ward for  Huntington’s disease patients was visited in order to include subjects in 
advanced  stages of Huntington’s disease, both institutionalized and attending a day clinic. These 
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subjects (n = 50) were selected on the basis of their physical and verbal capability to  participate; 
 severe  dysarthric and severely demented subjects were not approached. Fourth, a minority of 
the  subjects, called ‘spontaneous’ participants (10 presymptomatic and 8 symptomatic), were 
included with help of the Dutch Huntington’s disease patients’ association after posting an 
 announcement on their Internet site and in their quarterly.
Figure 1.  Flowchart of inclusion of subjects
CVA = Cerebrovascular accident; MMSE = Mini-Mental State Examination; UHDRS-m = Unified Huntington’s Disease Rating Scale, motor section
Subjects with juvenile-onset Huntington’s disease (n = 1) or concurrent diseases of the  central 
nervous system (e.g., cerebrovascular accident) (n = 4) were excluded, as well as mutistic 
 subjects (n = 8) and subjects who did not have a sufficient command of the Dutch language 
(n = 2). Forty-five outpatients were untraceable and 2 subjects were deceased. Of the  remaining 
299 subjects, 89 refused to participate because of various reasons including having no time, 
being too fatigued or too sick, and not wanting to be confronted with Huntington’s disease 
 (response rate 68.3%). Thus, we included 210 subjects, comprising 56 verified mutation 
 negative subjects and 154 verified mutation carriers. After the assessment, another 10 subjects 
were excluded because of severe cognitive disorders, 2 subjects declined during the study, and 
2 more mutation carriers were excluded because of an absent motor assessment, leaving 56 
non-carriers and 140 mutation carriers (Figure 1). The study was approved by the Medical Ethics 
Committee of Leiden University Medical Center, and all subjects gave informed consent.
Instruments
Demographic and clinical characteristics. Information on demographic and clinical  characteristics 
was collected using a standardized interview. Global functioning was assessed using the Total 
Functioning Capacity (TFC) subscale of the Unified Huntington’s Disease Rating Scale (UHDRS), 
a widely used standardized clinical rating scale for Huntington’s disease patients.13 The TFC 
 consists of 5 questions assessing employment; the capacity to handle financial affairs, manage 
domestic chores, and perform activities of daily living; and the care level provided. The TFC 
 ranges from 0 to 13 points, with lower scores indicating poorer functional abilities.14
CAG repeat length 
The number of CAG repeats of all subjects was verified, except for 1 symptomatic subject who 
died during the study. Subjects with a normal repeat length containing 26 or fewer copies and 
those with an intermediate repeat number between 27 and 35 were considered non-carrierss.15 
Since alleles in the 36 to 39 repeat range are unstable and are associated with the Huntington’s 
disease phenotype, these subjects were considered positive for Huntington’s disease in this 
study.
Assessment of motor functioning and disease stage
All subjects were examined for assessment of motor symptoms by a neurologist with experience 
of Huntington’s disease using the motor section of the UHDRS.13 The neurologist was blinded to 
the genetic status and the results of all other assessments of the subjects. On the basis of the 
clinical examination, the neurologist assigned a score indicating to what degree he or she was 
confident that the presence of an extrapyramidal movement disorder in a subject may be due 
to Huntington’s disease. This confidence-level score ranged from 0 to 4. Mutation carriers with 
a confidence-level score of 0 (normal) or 1 (nonspecific motor abnormalities, < 50% confidence) 
were classified as presymptomatic (n = 55). The remaining mutation carriers (n = 85) with a 
score of 2 to 4 (2 = motor abnormalities that may be signs of Huntington’s disease [50% - 89% 
confidence], 3 = likely signs of Huntington’s disease [90% – 98% confidence], 4 = unequivocal 
signs of Huntington’s disease [≥ 99% confidence]) were considered symptomatic. We further 
stratified motor symptomatic mutation carriers with confidence levels of 2 to 4 according to 
the total UHDRS motor scores as an ‘early disease stage’ group and an ‘advanced disease stage’ 
group using the median score (40 points) of the total UHDRS motor score (range, 0-124 points) 
as a cut-off.
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Diagnosis of psychiatric disorders
The Composite International Diagnostic Interview (CIDI),16 a fully structured, standardized 
 psychiatric diagnostic interview for disease classification according to the Diagnostic and 
 Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV),17 was administered by the 
 interviewers after certified training and under close supervision of a psychiatrist (EvD).
The sections for depression, mania, anxiety, obsessive compulsive disorder, and psychosis of the 
Dutch translation of the computerized edition of the CIDI, Version 2.1, were used to  assess the 
presence of each disorder in the past 12 months. The interrater reliability of the CIDI is excellent, 
and the test-retest reliability and validity are good.18 Because of lack of reliability in subjects with 
severe cognitive dysfunction, the CIDI was not administered in subjects with a score < 18 points 
on the Mini-Mental State Examination (MMSE) (range, 0 - 30 points).19 Raters for  psychiatric and 
cognitive functioning were deliberately informed about the genetic status of the participants, 
because nondisclosure on the side of the participant could considerably influence the subjects’ 
answers to questions about symptoms that are directly related to their genetic status.
Prevalences of psychiatric disorders in the general population were extracted from the 
 Netherlands Mental Health Survey and Incidence Study (NEMESIS),20 a prospective study of the 
prevalence, incidence, and course of psychiatric disorders using the CIDI in a representative 
sample of 7076 non-institutionalized Dutch adults aged 18 to 64 years.
Statistical analyses
Independent-samples t tests were used to compare group means of continuous variables, and 
Fisher exact  tests were used for comparison of dichotomous demographic characteristics and 
for pair wise comparison of prevalences of psychiatric disorders. All analyses were carried out 
two-sided, and, because of multiple testing, a significance level of p < 0.01 was applied.
Logistic regression analysis was applied to determine possible associations between various 
 demographic and clinical characteristics (age, sex, having a partner, having children, higher 
 education, psychiatric family history, CAG repeat length, total UHDRS motor score, and total 
MMSE score) and the presence of psychiatric disorders during the past 12 months in  mutation 
carriers. Nonlinear generalized canonical correlation analysis was conducted to determine 
 multiple clusters and the coincidence of symptomatic and presymptomatic subjects in each of 
the clusters.21
Results
Demographic and clinical characteristics
The 56 non-carriers and 140 mutation carriers differed significantly in many  demographic and 
 clinical characteristics (Table 1). Seven non-carriers had an intermediate CAG repeat length 
(range, 27 to 35 repeats), and 3 mutation carriers had a CAG repeat length between 36 and 
39 repeats, which is associated with a reduced penetrance. Subgroups of  presymptomatic and 
 symptomatic mutation carriers differed in age (mean = 40.8 years and 49.9 years,  respectively), 
having any children (mean = 63.6% and 82.4%, respectively), use of psychotropic  medication 
(mean = 21.8% and 55.3%, respectively), TFC score (mean = 12.0 points and 7.8 points, 
 respectively), MMSE score (mean = 28.1 points and 25.9 points, respectively), and having had 
higher education (mean = 63.6% and 44.7%, respectively) (data not shown). Logistic  regression 
analysis showed that only age (p = 0.003) and TFC (p < 0.001) were significant predictors, 
whereas the other covariates were not (p > 0.30). 
12-Month prevalences of psychiatric disorders
As is shown in Table 2, mutation carriers had significantly increased prevalences of  major 
 depressive disorder and obsessive-compulsive disorder compared to the Dutch general 
 population. Additionally, a trend of an increased prevalence of generalized anxiety disorder was 
found in mutation carriers compared to the general population (p = 0.02). Psychiatric  disorders 
were more prevalent, although not statistically significant, in mutation carriers  compared to 
 non-carriers. Non-carriers did not differ from the general population in prevalences of  psychiatric 
disorders.
The majority (n = 19, 52.8%) of the 36 mutation carriers with a psychiatric diagnosis had a 
single psychiatric disorder, 10 subjects had 2 psychiatric disorders, 6 subjects had 3 psychiatric 
 disorders, and 1 subject had 4 psychiatric disorders.
Analyzing presymptomatic and symptomatic mutation carriers apart, both groups showed 
 significantly increased prevalences of major depressive disorder (p = 0.001 and p < 0.001, 
 respectively) and obsessive-compulsive disorder (p = 0.003 and p = 0.01, respectively)  compared 
to the general population but not to non-carriers. In symptomatic subjects, prevalence of 
 non-affective psychosis was also significantly increased (p = 0.01). A trend was found for an 
increased prevalence of generalized anxiety disorder in both presymptomatic and  symptomatic 
mutation carriers (p = 0.03 and p = 0.02, respectively) compared to the general population 
 (Table 3).
Symptomatic mutation carriers did not differ in prevalences of psychiatric disorders from 
 presymptomatic mutation carriers (all p > 0.5). Discriminating symptomatic mutation  carriers 
into ‘early’ and ‘advanced’ symptomatic subjects according to their UHDRS motor score  revealed 
no significant differences either (data not shown, all p > 0.2).
Demographic and clinical characteristics associated with presence of psychiatric disorders 
Using logistic regression analysis, we found no significant associations between  demographic 
and clinical characteristics and the presence of psychiatric disorders among all mutation 
 carriers. Among presymptomatic mutation carriers only, a trend was found that subjects with a 
psychiatric disorder were younger compared to subjects without a psychiatric disorder (mean 
[SD] = 37.6 [8.8] years and 42.0 [10.7] years, respectively; p = 0.04). In addition, a somewhat 
higher mean UHDRS total motor score was found in presymptomatic mutation carriers with 
a  psychiatric disorder compared to presymptomatic mutation carriers without a psychiatric 
 disorder (mean [SD] = 3.5 [3.4] points and 1.9 [2.9] points, respectively; p = 0.02).
Using nonlinear generalized canonical correlation analyses, we found no clustering of 
 demographics, clinical characteristics, disease stage, and presence of psychiatric diagnoses.
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This study, using a fully standardized psychiatric interview, demonstrates that both 
 presymptomatic and symptomatic Huntington’s disease mutation carriers had significantly more 
formal DSM-IV diagnoses than the general population. Psychiatric disorders were also more 
 prevalent in mutation carriers compared to non-carriers, although not statistically  significant, 
probably due to a lack of power caused by the small groups. Contrary to our assumption, 
 however, non-carriers did not differ from the general population, although non-carriers shared 
the same potentially stressful environment with mutation carriers.
Affective disorder
Our study confirms an increased prevalence of depression in mutation carriers compared to the 
general population. Most earlier studies, however, measured symptoms of depression and not 
major depressive disorder meeting formal DSM criteria.10 Although presymptomatic mutation 
carriers showed a higher prevalence of major depressive disorder than did the population at 
large, the difference with non-carriers did not reach statistical significance (p = 0.06). This is 
in accordance with the only other study that used the CIDI in Huntington’s disease. This study 
reported an increased rate of current depressive symptoms but not formal depressive disorder 
in presymptomatic mutation carriers compared to non-carrierss.22
To date, the relationship between psychiatric phenotype and disease stage is unclear. Some 
 research indicates a decreased prevalence of depression in advanced disease stage  compared to 
presymptomatic stage.4,23 However, psychiatric assessment in the advanced stage of  Huntington’s 
disease may be hampered by cognitive deterioration and the increase of physical symptoms. For 
example, weight loss and disturbed sleeping could be symptoms of  neuroendocrine  disturbances 
in Huntington’s disease as well as symptoms of depression.  Therefore, in advanced symptomatic 
patients, other diagnostic tools like observation of  behavior and relatives’ information should be 
part of the clinical examination.
Prevalences of dysthymia, mania, or bipolar disorder did not differ between our study groups, 
nor has a difference been reported in earlier studies. One study using DSM criteria reported an 
increased prevalence of manic symptoms in presymptomatic mutation carriers compared to 
non-carriers, but these symptoms did not fulfill diagnostic criteria for bipolar disorder.23
Anxiety disorder
Several studies reported increased prevalence of anxiety,10 but in this study we found only 
a non-significant trend of an increased prevalence of formal generalized anxiety disorder in 
 Huntington’s disease. Most studies, though, used measures with general questions about 
 anxiety, worrying, and tensed feelings, e.g., the behavioral section of the UHDRS,13 resulting in 
rates of anxiety symptoms as high as 34% to 61%.10
 
Obsessive-compulsive disorder
We found an increased prevalence of obsessive compulsive disorder in mutation carriers 
 compared to the general population, both in presymptomatic and in symptomatic mutation 
carriers, whereas until now, occurrence of formal obsessive-compulsive disorder has been 
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described only in case reports, both before24-26 and after27 the onset of motor symptoms. 
 Increased prevalences of obsessive and compulsive symptoms, however, have been reported 
 previously.28-30 Especially in later stages of Huntington’s disease, a more than 3 times greater 
probability of obsessive compulsive symptoms in comparison to subjects at 50% risk has been 
described.31
Psychosis
Contrary to the literature10 and our expectations, the prevalence of non-affective  psychosis 
in symptomatic mutation carriers in our study was rather low. This may be due to the use 
of strict DSM-IV criteria, our predominantly outpatient population, and the exclusion of 
subjects in an  advanced disease stage with serious cognitive deterioration. Furthermore, 
 symptomatic  mutation carriers used much more psychotropic medication than presymptomatic 
 mutation  carriers, which could have suppressed psychiatric symptoms. In particular, the use 
of the  neuroleptic tiapride in symptomatic mutation carriers, which is prescribed for motor 
symptoms, may have effectively reduced psychotic phenomena.32,33 This fact would lead to an 
 underestimation of psychosis, particularly in symptomatic mutation carriers.
Environmental and biological factors
We could not confirm our assumption that Huntington’s disease family members who were not 
genetically compromised had more psychiatric disorders than the general population, although 
they shared a potentially stressful environment. Early life experiences, such as insecure parental 
binding, the stress of being at risk, and the familial disease burden, do not make them more 
susceptible to psychiatric disorders compared to the general population. This finding indicates a 
predominantly neurodegenerative origin of psychiatric disorders in Huntington’s disease.
As the Huntington’s disease mutation itself does not show a full penetrance for the presence 
of psychiatric disorders, future research should focus on the contribution of other factors, both 
environmental and biological. Besides playing a part in the risk profile for psychiatric disorders, 
biological factors may also be markers for disease progression. Since pre-motor symptomatic 
mutation carriers with a psychiatric disorder have a significantly higher UHDRS total motor  score 
compared to presymptomatic mutation carriers without a psychiatric disorder, research on 
 early neuroendocrine and neuroanatomical changes in relation to the occurrence of  psychiatric 
 disorders — before the manifestation of movement disorders — is warranted. Although  imaging 
studies on psychopathology in Huntington’s disease are rare, a decreased metabolic activity 
in orbital frontal-inferior prefrontal regions has been described in depressed Huntington’s 
disease patients,34 and disturbed anatomical connections between the basal ganglia and the 
limbic  system have been suggested in Huntington’s disease patients with obsessive-compulsive 
 disorder,35 all of which require further research.
To our knowledge, this is one of the largest studies among Huntington’s disease mutation  carriers 
in which a validated and fully structured instrument was used to estimate the  prevalences of 
psychiatric disorders according to DSM-IV classification. The use of a control group of first- 
degree non-carriers relatives is an important strength of this study. A possible limitation of our 
study is that both interviewers and study subjects had knowledge of their genetic status. In a 
previous study, subjects who were mostly well informed about the symptoms accompanying 
disease onset tended to conceal symptoms from the interviewer to avoid disclosure of their 
 genetic status.36 Therefore, interviewers were not blinded for the genetic status of  participants, 
as this would potentially generate a biased response (underreport) on questions about 
 psychiatric symptoms. This may have contributed to increased scores of psychiatric symptoms in 
mutation carriers. On the other hand, the prevalences of psychiatric disorders might have been 
 underestimated, since those with psychiatric symptoms might have been more likely to refuse 
participation.37 Furthermore, relatively small sample sizes and low rates of psychiatric disorders 
may have compromised the power to detect differences between the study groups.
This study highlights the importance of exploring the full clinical phenotype of Huntington’s 
disease before motor symptoms arise. The presence of a potentially treatable psychiatric 
 disorder contributes greatly to disease burden and should therefore be a constant point of 
 attention for all who work with Huntington’s disease patients and their families. 
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Objective: To investigate behavioral problems in Huntington’s disease.
Method: In 152 Huntington’s disease mutation carriers and a control group of 56 non-carriers 
at initial 50% risk, the Dutch version of the Problem Behaviors Assessment was administered. 
Mutation carriers were divided into three groups according to the motor section of the Unified 
Huntington’s Disease Rating Scale: pre-motor symptomatic, early and advanced symptomatic 
subjects. The factor structure and interrater reliability of the Problem Behaviors Assessment 
were investigated.
Results: The clinically relevant interrater reliability of the Problem Behaviors Assessment was 
0.82 for severity scores and 0.73 for frequency scores. The Problem Behaviors Assessment 
 showed a three-factor solution: apathy, depression and irritability. Mutation carriers, including 
presymptomatic subjects, portrayed more apathy, depression and irritability than non-carriers. 
Early symptomatic subjects had more apathy, but not more depression or irritability,  compared 
to presymptomatic subjects. Advanced symptomatic subjects had more apathy than early 
 symptomatic subjects.
Conclusions: The Problem Behaviors Assessment is a reliable and sensitive instrument. 
 Behavioral problems occur in all stages of Huntington’s disease and arise before the onset of 
motor symptoms. Apathy is related to disease severity, whereas depression and irritability are 
not. The broad clinical phenotype of Huntington’s disease therefore requires adequate service 
delivery with integrated and multidisciplinary patient care. 
Introduction
Huntington’s disease is a progressive autosomal dominant neurodegenerative disorder with 
an elongated CAG repeat length on chromosome 4. It has an insidious onset (mean age 40 
years) and varied clinical presentation.1 Huntington’s disease is traditionally characterized by 
 movement disturbances whilst cognitive deterioration is now well documented.2 Increasingly, 
however, neuropsychiatric symptoms are recognized as much more distressing and disabling for 
both subjects and their caretakers, and are often the main reason for institutionalizing.3
A systematic review of the literature showed that the reported prevalences of depressed mood, 
anxiety, irritability and apathy vary from 33% to 76%, whereas obsessive compulsive symptoms 
and psychosis occur less often with a prevalence of 10 - 52% and 3 - 11%, respectively.4 An 
 evaluation of available studies on psychopathology in Huntington’s disease is difficult because of 
different methodologies, small sample sizes and lack of control groups.4,5 Because  Huntington’s 
disease is uncommon and complex, and behavioral symptoms are often not described as a 
 major part of the disease process, the symptoms, course and management may be relatively 
unknown to health care professionals.
Some evidence exists that cognitive deterioration precedes the onset of motor symptoms in 
Huntington’s disease.6,7 Several retrospective studies indicate that the same might be the case 
for psychopathology.8-12 Only four cross-sectional studies comparing pre-motor  symptomatic 
mutation carriers with non-carriers have been done so far.13-16 Although they found no 
 difference for past or present psychiatric morbidity, they did find that presymptomatic mutation 
carriers differed from non-carriers on measures of irritability and anger/hostility. We therefore 
 propose that behavioral problems, especially irritability, precede the onset of motor symptoms 
in  Huntington’s disease.
The etiology of neuropsychiatric symptoms is likely to be complex, implicating firstly direct 
 neuropathological effects by the disease itself 17 and, secondly, social and environmental  causal 
factors.9-10 An appropriate control group for genetically confirmed Huntington’s disease  mutation 
carriers is therefore their mutation-negative siblings. They share the same  psychosocial family 
background, often strongly influenced by an ill parent, as well as other risk factors that could 
contribute to the development of behavioral problems.18 These include being at-risk for many 
years, as well as participating in the presymptomatic testing procedure until the outcome is 
known. We suppose that part of the behavioral problems in Huntington’s disease is due to 
 direct disease processes and therefore expect that mutation carriers portray more behavioral 
 problems compared to their mutation-negative siblings.
The aim of our study was to investigate the prevalence of psychopathology and  behavioral 
 problems in (a) a sample of genetically and clinically confirmed Huntington’s disease 
 mutation  carriers, comprising both the early and advanced stages of the disease; (b) a group 
of  presymptomatic mutation carriers; and (c) a control group of mutation-negative subjects 
at  initial 50% risk. Because neuropsychiatric symptoms in subjects with neurodegenerative 
 disorders cannot often be grouped according to formal psychiatric classifications,19 a  dimensional 
 approach may better be used to illuminate neuropsychiatric symptomatology.20 We therefore 
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use the Problem Behaviors Assessment (PBA)  (See: Appendix A) to assess behavioral problems 
in this study. The PBA is a semi-structured interview specifically designed for a more reliable 
assessment and better understanding of behavioral problems in Huntington’s disease. Craufurd 
et al.21 described three clusters of symptoms — apathy, irritability and depression — based on 
a factor analysis using data from 78 subjects. They also reported an interrater reliability of 0.86 
for severity scores and 0.84 for frequency scores.
The PBA is a promising instrument, but Craufurd et al. did not include a sufficiently large  sample 
in their factor analysis.21 We therefore re-assess the factor structure and determine the inter-
rater reliability of the Dutch translation of the PBA.
Methods
Participants
Between May 2004 and August 2006, 343 genetically tested subjects at initial 50% risk of  Huntington’s 
disease were contacted via the Departments of Neurology and Clinical  Genetics of the Leiden Uni-
versity Medical Centre and long-term care facility ‘Overduin’ in the  Netherlands. One hundred and 
ninety-two subjects were willing and able to participate in this study.  Subjects with a neurological 
condition other than Huntington’s Disease were excluded. An additional 18 subjects were recruited 
through other means, such as the Dutch Huntington’s Disease  association, but two subjects were 
subsequently lost to follow-up. The remaining 208  subjects were divided into four groups based on 
(a) their genetic test result, which was obtained from their medical records, and (b) their Unified 
Huntington’s Disease Rating Scale (UHDRS)  motor score (Figure 1).22 The Medical Ethical Committee 
of the Leiden University Medical Centre  approved the study. All subjects gave informed consent.
CAG repeat length
The number of CAG repeats of all subjects was verified. Subjects with a normal repeat length 
containing 26 or less copies and those with an intermediate repeat number between 27 and 35 
were considered non-carriers.1 Since alleles in the 36 to 39 repeat range are unstable and are 
associated with the Huntington’s disease phenotype, these subjects were considered positive 
for Huntington’s disease in this study.
Interview
All subjects were interviewed by trained interviewers who collected socio-demographic data 
and administered all measures, except for the motor section of the UHDRS. In a previous  study,6 
subjects who are mostly well informed about the symptoms accompanying disease onset 
 tended to conceal symptoms from the interviewer if they were to keep their genetic status 
secret. Therefore interviewers were not blinded for the genetic status of participants, as this 
would result in an underreporting of behavioral problems.
Assessment of motor functioning and disease stage
The motor section of the UHDRS was assessed by a neurologist who was kept blind for the 
 genetic status of the subject. Based on the clinical examination, the neurologist expressed his 
confidence that the presence of motor symptoms in a study subject is a sign of clinically  manifest 
Huntington’s disease. Confidence level scores range from 0 to 4. All mutation  carriers (n = 55) 
with confidence level scores of 0 and 1 were classified as presymptomatic. The  remaining 
 mutation carriers (n = 97) with score 2 to 4 were all considered symptomatic. The median score 
(40 points) of the total UHDRS motor score (range 0 - 124 points) was used for distinguishing 
early symptomatic (n = 47) from advanced symptomatic subjects (n = 50) (Figure 1).
Figure 1.  Flowchart of inclusion of subjects
CVA = Cerebrovascular accident; UHDRS-m = Unified Huntington’s Disease Rating Scale,  motor section
Assessment of neuropsychiatric symptoms
Behavioral problems were assessed with the PBA which consists of 36 items covering nearly 
all behavioral problems present in Huntington’s disease.21 The 5-point PBA rating scales, one 
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 subscale for severity and one for frequency, are modeled after the behavioral section of the 
UHDRS, using the scores 0 (absent) 1 (questionable), 2 (mild), 3 (moderate) and 4 (severe). 
Unlike the UHDRS, which rates behavior in the last 6 months, the PBA solely assesses behavioral 
problems in the 4 weeks prior to the interview.
Where possible, subjects were interviewed in the presence of a knowledgeable informant. 
If not, we conducted a telephone interview with an informant. Both the informant and the 
 subject were given the opportunity to speak with the interviewer separately, in order to acquire 
 information that might have been kept from us in the presence of the other person. Scores 
were determined by the interviewer based on the combination of information gathered, which 
included clinical observations.
In order to assess the interrater reliability of the PBA, a random subset of 63 subjects and their 
informants were interviewed a second time on the same day by a different interviewer. For the 
methodological evaluation [principal component analysis (PCA)] of the PBA, the PBAs of 152 
mutation carriers only were used. These were augmented with a further group of 25 PBAs of 
mutation carriers who were assessed as part of ordinary monitoring. This resulted in a total of 
177 PBAs for the methodological evaluation.
For this study a Dutch translation of the PBA was created. The Dutch PBA was translated back 
into English by a native English speaker which resulted in a few linguistic changes only.
Other clinical characteristics
Information on sociodemographic and clinical characteristics was obtained during a  standardized 
interview. The estimated age of onset was calculated according to the following equation: log 
(age) = α + β (CAG number repeats), where α = 6.15 and β = −0.053.23
The Total Functional Capacity (TFC) scale was administered to assess general functioning. The 
TFC is widely used in Huntington’s disease research, with scores ranging from 0 to 13 points.24 
A lower score indicates worse general functioning. The Mini-Mental State Examination (MMSE) 
was used to assess global cognitive functioning. A score below 25 (out of 30) is used as  indication 
of cognitive impairment.25
Statistical analysis
Group differences on demographic and clinical characteristics were determined using  one-way 
ANOVA. Post hoc comparisons were carried out with the Scheffé method for differences between 
groups for continuous data. Chi-square tests with adjusted standardized residuals were used for 
analysis of dichotomous data.
Interrater reliability of the PBA was assessed using weighted kappas. A kappa of more than 0.6 
is considered acceptable and a kappa of more than 0.8 is considered good.26 Because we only 
considered differences of more than 1 point between the raters as clinically relevant, a ‘clinically 
relevant’ kappa was calculated, which only included differences that were larger than 1 point.
The factor structure of the PBA was determined using PCA with varimax rotation. Items 
 occurring in less than 10% of subjects were excluded (i.e., change in food preference, 
obsessions,  somatization, sexually disinhibited behavior, sexually demanding behavior, 
 delusions, jealousy and all forms of hallucinations). The PBA scores (the product of severity 
and frequency scores) of the resulting 28 items were entered into an analysis of 177 cases. 
The  solution was checked for robustness by randomly deleting 10% of the cases, which was 
 repeated five times. The  quantity of factors was based on a Monte Carlo analysis and a scree 
plot. Based on the results of the PCA, three internally consistent subscales were computed. 
Alpha maximization was used as a criterion for including items in a subscale. The subscale  scores 
were computed as the mean of the included items, resulting in a theoretical range from 0 to 
16. The subscale scores of the different groups were compared using analyses of covariance 
(ANCOVA), with sex, education and psychiatric history as covariates, to distinguish between the 
groups. Because these scores are not normally distributed, a square root transformation was 
applied. Significance for all tests was set at p < 0.05. Kappas were computed in Microsoft Excel. 
All other analyses were carried out in Statistical Package for Social Sciences v. 12.0.1.
Results
Socio-demographic and clinical characteristics The main socio-demographic and clinical 
 characteristics of the study population are given in Table 1. A significantly lower CAG repeat 
length was found in presymptomatic compared to symptomatic mutation carriers (p < 0.05). The 
calculated mean number of years to the estimated age of onset in presymptomatic mutation 
carriers was 8 years. Both early and advanced symptomatic mutation carriers had significantly 
lower mean MMSE scores than presymptomatic mutation carriers and non-carriers (p < 0.05). 
All groups differed significantly from each other with respect to TFC and the use of psychotropic 
drugs. Presymptomatic mutation carriers significantly more often reported a psychiatric history 
than the three other groups. This was corrected for in the subsequent analyses (ANCOVA).
Assessment of PBA
The interrater reliability of the PBA was 0.82 (95% CI = 0.65 – 1.00) for severity scores and 0.73 
(95% CI = 0.47 – 1.00) for frequency scores, as measured with a ‘clinically relevant kappa’.
Factor analysis revealed three components that together explained 38.6% of the variance  (Table 
2). Although Monte Carlo analysis allowed for four principal components, the scree plot  indicated 
three components comprising coherent items. Based on the PCA three internally  consistent 
 subscales — apathy, depression and irritability — were computed. Alpha  maximization was used 
as criterion for including items in a subscale. Internal consistencies expressed as Cronbach’s α 
were 0.84 for apathy, 0.81 for depression and 0.67 for irritability. The subscales turned out to 
be sufficiently stable. In the five tests performing a PCA on random subsamples of 90% of the 
cases, the same components emerged. Some minor shifts of items to another component were 
observed; one or two in each test. These items included ‘insomnia’ (4×), ‘impaired  judgment’ 
(2×), ‘loss of energy’ (2×), and ‘self-centeredness’ (1×). Only this last item was used in the 
 construction of a subscale (irritability).
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Table 2. Principal Component Analysis on PBA items *
 Component loadings
 Apathy Depression Irritability
   
Lack of perseverance .80 .16 .02
Poor quality of work .79 .12 .03
Lack of initiative .72 .28 -.07
Poor self-care .71 .01 .01
Blunting of affect .53 .27 -.06
Bolting food .49 -.20 .12
Los of energy .43 .31 .23
Loss of libido .42 .20 .01
Sleeping or drowsy during day .41 .06 .26
Pathological preoccupations .40 .09 .26
Depressed mood .21 .79 .10
Depressive cognitions .30 .73 -.02
Anxiety .08 .70 .11
Tension -.02 .67 .14
Suicidal ideation .23 .64 -.02
Reduced appetite .19 .45 .00
Early wakening -.09 .38 .06
Loss of volition .28 .38 -.04
Impaired judgment .30 .31 .27
Irritability .28 .22 .67
Aggression -.08 .06 .65
Verbal outbursts .03 .10 .60
Inflexibility .40 .03 .50
Disturbed temperature regulation -.04 .06 .48
Self centered, demanding .42 .11 .45
Increased appetite -.03 -.11 .43
Compulsive behaviors .20 -.04 .41
Initial insomnia -.05 .34 .37
   
% Variance 15.6 13.2 9.8
Cronbach’s alpha # 0.84 0.81 0.67
* For the Principal Component Analysis (PCA) data from the Problem Behaviors Assessments of another 25 subjects were added (42% males; 
mean age: 46 years, SD 7.7 years) resulting in a group of 177 genetically confirmed mutation carriers. The items that are used for the  subscales 
are in bold italics.
# Alpha maximization was used as a criterion for including items in a subscale.
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Behavioral problems in Huntington’s disease
Comparison of the subscale scores of the different study groups revealed significantly more 
apathy, depression and irritability in all mutation carriers than in non-carriers (Table 3). 
 Presymptomatic mutation carriers showed more apathy, depression and irritability compared 
to non-carriers, whereas they differed from early symptomatic mutation carriers on measures 
of apathy only. Advanced mutation carriers revealed more apathy than the earlier disease stage 
groups, but not more depression and irritability (Table 3).
No significant relationships were found between the three subscale scores and the estimated 
age of onset of motor symptoms in mutation carriers.
Discussion
The PBA appears to be a promising instrument for the assessment of behavioral symptoms in 
Huntington’s disease. The instrument shows a good interrater reliability, is easy to  administer and 
covers a broad range of behavioral problems. The PBA also facilitates a dimensional  approach, 
which seems appropriate for the assessment of behavioral problems in Huntington’s disease.19
The PCA conducted on this instrument gives a robust solution. It features three  subscales: 
 apathy, depression and irritability. Our subscales are roughly similar to the factors found 
by  Craufurd et al.,21 although their sample was rather small for a reliable factor analysis.27 
 Measuring the  correlation between external measures of apathy, depression, irritability and 
the relevant  factors on the PBA could provide further evidence for the existence of different 
neuropsychiatric syndromes in Huntington’s disease.
A disadvantage of the PBA is its comparative length, but the instrument can be considerably 
reduced whilst retaining most of the advantages listed. We recommend leaving out all the items 
that have been excluded from the factor analysis, which reduces the amount of items from 36 
to 28. If necessary the PBA could be reduced to the 14 items that constitute the three factors. 
Because the PBA does not generate formal psychiatric diagnoses, the instrument may be used 
alongside traditional psychiatric measures. The PBA is very likely to have a greater sensitivity for 
behavioral problems in Huntington’s disease, whereas formal psychiatric diagnostic instruments 
provide greater specificity.
A comparison of symptomatic and presymptomatic mutation carriers and a control group 
 consisting of non-carriers at initial 50% risk shows that all mutation carriers portray more 
 apathy, depression and irritability than the control group. This difference is apparent even 
 before motor symptoms arise. Although some psychopathology in the mutation carrier group 
may be due to knowledge of a Huntington’s disease positive test result, a negative result also 
produces  psychological problems, such as survivors’ guilt. No substantial long-term effects of 
test results have been found.28 Therefore the difference between mutation carriers and the 
control group is directly due to neuropathology, rather than to psychosocial stressors such as a 
disturbed  childhood and anxiety about test results.
These findings give strong evidence that behavioral problems are amongst the first disease 
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symptoms in Huntington’s disease and, in keeping with our hypothesis, can precede the 
 onset of motor symptoms. Since our presymptomatic group also had reduced total functional 
 capacity compared to non-carriers, clinically manifest Huntington’s disease can present itself 
before the onset of motor symptoms. This contradicts previous literature, which only found a 
difference between presymptomatic and non-carriers for irritability.13-15 The PBA, facilitating a 
 multidimensional approach, may have been more sensitive than the instruments used in other 
studies.
Recognition and acknowledgement of these behavioral changes as part of the clinical  phenotype 
of Huntington’s disease will help carriers and their families cope with this disease. General 
 practitioners should be aware of these specific characteristics in subjects at risk for Huntington’s 
disease, because in many carriers the negative impact of Huntington’s disease may start long 
before the first motor symptoms occur. Possible interventions in general practice are family 
support and psycho-education about the broad spectrum of disorders in Huntington’s disease. 
Furthermore, multidisciplinary treatment with general practitioners, psychiatrists,  psychologists, 
neurologists, nurses and social workers will contribute to the care of these  patients and the 
 quality of their lives.29
Presymptomatic and early symptomatic mutation carriers differed on measures of apathy only, 
as do early and advanced symptomatic mutation carriers. This confirms earlier evidence that 
apathy is strongly correlated to disease progression.21,30-34 Depression and irritability appear to 
be not related to disease stage at all, with consistent levels found in pre-, early and advanced 
symptomatic subjects.
A possible limitation of our study is that both interviewers and study subjects had knowledge of 
their mutation status. This may have contributed to increased scores of behavioral problems in 
mutation carriers. Blinding interviewers to the genetic status of the participant requires subjects 
to keep their status secret. Experience has shown that this would generate a biased response on 
questions about emotional problems which could be related to genetic status or be perceived 
by the subject or informant as related to disease onset. The interviewers were aware of this 
 limitation, and in order to guarantee objectivity, frequent interrater sessions were held and 
disease progression was assessed separately, and blindly, by a neurologist.
This is the first study that incorporates various Huntington’s disease stages and a control 
group of non-carriers at initial 50% risk and gives clear evidence for the early emergence of 
behavioral problems in Huntington’s disease. These symptoms are at least partly due  directly 
to  neuropathological processes. Since behavioral problems are amongst the most  distressing 
symptoms for caregivers and patients,3 recognition and multidisciplinary treatment are  vital. The 
PBA seems to be an appropriately sensitive instrument for assessment of behavioral  problems. 
Overall, these findings provide strong support for increasing the emphasis on  neuropsychiatric 
symptoms in Huntington’s disease in both research and clinical care. 
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Abstract
Objective: To investigate the concurrent validity of two dimensional rating scales that were 
designed for assessment of psychopathology in Huntington’s disease, with categorical DSM-IV 
diagnoses.
Background: Assessment of psychopathology in Huntington’s disease using formal criteria is 
complex due to the co-morbid somatic and cognitive disturbances, and diminished disease 
 awareness.
Method: In 152 Huntington’s disease mutation carriers, test scores on the Problem  Behaviors 
 Assessment scale (PBA) and the behavioral section of the Unified Huntington’s Disease 
 Rating Scale (UHDRS-b) were associated with DSM-IV diagnoses according to the Composite 
 International Diagnostic Interview (CIDI).
Results: Both high PBA and UHDRS-b scores corresponded with presence of DSM-IV diagnoses. 
Receiver operating characteristic curves showed an area under the curve of 0.87 for the PBA and 
0.91 for the UHDRS-b, demonstrating moderate to strong discriminatory power. Using  caregiver 
information, subjects who were too cognitively impaired for CIDI assessment showed similar 
high PBA and UHDRS-b scores, with both a negative predictive value of 96% and a positive 
 predictive value of 40% and 44% respectively, for the presence of formal psychiatric disorders.
Conclusion: The use of dimensional rating scales and caregiver information allows for the 
 assessment of psychopathology in advanced stage Huntington’s disease, also in the presence 
of cognitive impairment. 
Introduction
Huntington’s disease is a progressive neurodegenerative disorder with an autosomal  dominant 
hereditary pattern, caused by an elongated CAG repeat on chromosome 4.1 Huntington’s 
disease is clinically characterized by progressive motor dysfunction, psychiatric disorders and 
cognitive dysfunction. Typically, first clinical symptoms appear between the age of 30 and 50 
years,  showing a progressive course and disease duration of 15 to 20 years.
The presence of psychiatric disorders in Huntington’s disease is associated with poor quality of 
life and increased caregiver distress, and it hastens admission to nursing homes.2-4  Depression 
is the most frequently reported psychiatric disorder, but neuropsychiatric symptoms such as 
 irritability and apathy are also highly prevalent in Huntington’s disease.5,6 Because some of 
the non-emotional symptoms of psychiatric disorders overlap with the typical symptoms of 
 Huntington’s disease, these may influence the validity of psychiatric assessment, e.g. weight 
loss may be a symptom of depression, but can also be an isolated symptom of Huntington’s 
disease.7 Besides, Huntington’s disease patients frequently show lack of insight in advanced 
 stages, and may not be able to communicate.8,9 Assessment of psychiatric disorders may  thereby 
be  considerably hampered and even impossible, although in fact patients may suffer from gross 
psychopathology leading to severe functional impairments.
The current generally accepted diagnostic classification of psychiatric disorders is the  Diagnostic 
and Statistical Manual, Fourth edition (DSM-IV-TR).10 The DSM utilizes a non-etiological, 
 categorical approach according to a subset of strict criteria to assign a psychiatric diagnosis at a 
certain time. This approach is useful in physically healthy subjects, but has major limitations in 
patients with a neurodegenerative disorder.
These limitations raise the question whether diagnostic classification of psychiatric disorders 
 according to the DSM is reliable and valid in Huntington’s disease. For that reason, the use of 
dimensional rating scales that use caregiver information for the assessment of  psychopathology 
has been suggested as more appropriate in clinically affected Huntington’s disease  patients.11,12 
Such an approach may better reflect the range of symptoms across the spectrum of 
 psychopathology than a DSM diagnosis.
In this study, we hypothesized that dimensional measurement using caregiver information is 
appropriate to detect psychopathology in advanced Huntington’s disease. We assessed the 
concurrent validity of two dimensional rating scales that were specifically designed for the 
 assessment of psychopathology in Huntington’s disease, compared to a categorical assessment 
of psychiatric disorders as defined by DSM-IV criteria.
Methods
Subjects
Between May 2004 and August 2006, 152 consecutive Huntington’s disease mutation carriers 
with a repeat length of 36 or more were recruited from the out-patient departments of Clinical 
Genetics and Neurology of the Leiden University Medical Center (LUMC), and from a regional 
nursing home. The design of the study has been described in detail elsewhere.13 All subjects 
70
Chapter 5  -  M
easurem
ent of psychopathology in H
untington’s disease: the critical role of caregivers
71
gave written informed consent. The study was approved by the Medical Ethical Committee of 
the LUMC.
Instruments
Demographic and clinical characteristics
Information on demographic and clinical characteristics was collected using a standardized 
 interview. CAG repeat length of all subjects was known, except for one subject who died during 
the study. Estimated age of onset was calculated according to the formula of Vassos et al.: ln 
[age of onset (years)] = 6.18 - 0.054 * [CAG repeats (number)].14 Global functioning was  assessed 
using the Total Functioning Capacity (TFC; range 0-13 points, with lower scores indicating  worse 
performance) of the Unified Huntington’s Disease Rating Scale (UHDRS).15 Global cognitive 
 functioning was assessed with the Mini-Mental State Examination (MMSE; range 0-30 points, 
with lower scores indicating worse performance).16 Subjects were examined for assessment 
of motor symptoms by a neurologist with experience of Huntington’s disease using the motor 
 section of the UDHRS (range 0-124 points, with higher scores indicating worse performance).17 
General assessment of psychopathology
Composite International Diagnostic Interview
The Composite International Diagnostic Interview (CIDI) is a fully structured  standardized 
 psychiatric diagnostic interview for disease classification.18 The CIDI aims to identify the 
 extent to which endorsed symptoms satisfy diagnostic criteria for one of the mental disor-
ders  according to DSM-IV. The sections for depression, mania, anxiety, obsessive-compulsive 
 disorder and  psychosis of the interviewer administered version of the CIDI Version 2.1 were 
used to assess the presence of these Axis I disorders in the month prior to the interview. The 
inter-rater  reliability of the CIDI is excellent, and the test-retest reliability and validity are good.19 
Subjects with an MMSE score < 18 points were considered too cognitively impaired for a reliable 
formal assessment with the CIDI.
Huntington’s disease specific rating scales for psychopathology
Problem Behaviors Assessment
The Problem Behaviors Assessment (PBA) (See: Appendix A) is a recently developed  instrument 
for the assessment of the severity and frequency of behavioral problems in Huntington’s 
disease.20 The PBA is a semi-structured interview designed for use with both patients and their 
caregivers. The severity and the frequency of each of the 36 items are scored on a scale from 
0 to 4, with higher scores indicating more psychopathology. The severity and the frequency 
scores are multiplied to assess the total score for each item. The sum of these scores is called 
the PBA score (range 0 - 576). Previously, we performed a factor analysis on the 36 items of 
the PBA,21 and distinguished three underlying symptom dimensions: ‘apathy’ (consisting of four 
items: lack of perseverance, poor quality of work, lack of initiative, and poor self-care; range 
0 - 64 points), ‘depression’ (five items: depressed mood, depressive cognitions, anxiety, tension, 
and suicidal ideation; range 0 - 80 points), and ‘irritability’ (five items: irritability, aggression, 
verbal outbursts, inflexibility, and self-centered, demanding behavior; range 0 - 80 points). The 
interrater reliability of the PBA in a mixed population of Huntington’s disease mutation carriers 
was 0.82 for severity scores and 0.73 for frequency scores.21
Behavioral section of the Unified Huntington’s Disease Rating Scale
The behavioral section of the UHDRS (UHDRS-b) (See: Appendix B) consists of 11 items for the 
assessment of neuropsychiatric symptoms in a four weeks period.17 Severity and frequency 
of these symptoms are scored on a scale from 0 to 4, with higher numbers indicating more 
 psychopathology. The sum of the product of severity and frequency scores of all items is the 
UHDRS-b score (range 0 - 176).
Caregivers
Ratings of the PBA and the UHDRS-b are based on the reports of the subject and his/her 
 caregiver, together with the clinical impression of the interviewer. Caregivers of the subjects 
who were too cognitively impaired for the CIDI consisted of nurses (58%), partners (25%), and 
children (17%). Caregivers of the other subjects were partners (60%), siblings (13%), parents 
(10%), children (7%), and the remaining 10% were assessed in the absence of a caregiver.
Statistical analyses
The three study groups were compared using independent samples t-tests for continuous 
 variables and chi-square (χ2) tests for dichotomous variables and for pair-wise comparison. 
All analyses were carried out two-sided with a significance level of p < 0.05. Non-parametric 
 Kruskal-Wallis one-way analysis of variance was applied for testing differences between the 
groups for variables with skewed distributions.
Receiver operating characteristic (ROC) analysis was done to compare the results with the PBA 
as well as the UHDRS-b to classification of subjects according to DSM-IV diagnosis as assessed 
with the CIDI, and to select optimal cut-off scores for screening and diagnostic purposes of these 
two scales.22 ROC curves were plotted for Huntington’s disease patients with a DSM-IV  diagnosis, 
as well as for the combined group of Huntington’s disease patients with a DSM-IV diagnosis and 
Huntington’s disease patients in whom formal CIDI assessment was not possible. These curves 
yielded the ‘sensitivity’ versus ‘1 minus the specificity’ for each possible cut-off point. Optimal 
cut-off points were determined by assessing which score combined maximum sensitivity and 
specificity. The area under the ROC curve (AUC) was used as an indicator of  diagnostic test’s 
discriminatory power to distinguish between subjects with and without a  DSM-IV diagnosis.23 
An AUC < 0.75 was considered not clinically useful. 
Results
Demographic and clinical characteristics
Nineteen (13.6%) of the 140 subjects had one or more psychiatric disorders according to the 
CIDI (Table 1). Ten of them (52.6%) of the 19 subjects with a psychiatric diagnosis had a single 
psychiatric disorder; five subjects (26.3%) had two psychiatric disorders, three subjects (15.8%) 
had three psychiatric disorders, and one subject (5.3%) had even four. Most frequently reported 
psychiatric disorders were major depressive disorder (n = 8) and obsessive-compulsive disorder 
(n = 7).
Table 1 shows the demographic and clinical characteristics of 121 subjects without a formal 
DSM-IV diagnosis, 19 subjects with a formal DSM-IV diagnosis, and 12 subjects that were too 
cognitively impaired. These latter subjects showed characteristics of advanced Huntington’s 
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Figure 1.  Histograms and ROC curves for the PBA and UHDRS-b scores of the three study groups among 152 Huntington’s 
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UHDRS-b = Unified Huntington’s Disease Rating Scale, behavioral section 
  
disease stage including decreased TFC score, increased total UHDRS-motor (UHDRS-m) score, 
and the use of significantly more neuroleptics, in comparison with the two other study groups.
PBA and UHDRS-b scores in relation to presence of DSM-IV diagnoses
There was a significant difference between the three study groups for both the PBA (sub) scores 
and the UHDRS-b score (Table 2). All median PBA (sub) scores and the UHDRS-b score were 
 significantly higher in subjects with a DSM-IV diagnosis compared to subjects without a  DSM-IV 
diagnosis (all p < 0.05). Also, subjects to whom the CIDI could not be administered  because 
of severe cognitive dysfunction showed a significantly higher total PBA score, PBA apathy 
 subscore, and UHDRS-b score compared to those without a DSM-IV diagnosis. No statistically 
significant differences were found between the cognitively compromised group and subjects 
with a  DSM-IV diagnosis. As is shown in Figure 1A, high PBA and UHDRS-b scores indicate severe 
and frequent psychopathology in the cognitively compromised group.
Figure 1. istograms and ROC curves for the PBA and UHDRS-b scores of the three study groups 
among 152 Huntington’s disease mutation carriers
PBA = Problem Behaviors Assessment; UHDRS-b = Unified Huntington’s Disease Rating Scale, behavioral section; CIDI = Composite International 
Diagnostic Interview
Validity of PBA and UHDRS-b compared to DSM-IV
To assess the concurrent validity of the two Huntington’s disease specific rating scales, the CIDI 
was considered to be the gold-standard. The ROC curves showed an AUC for the group with 
a DSM-IV diagnosis of 0.87 for the PBA and 0.91 for the UHDRS-b (Figure 1B), demonstrating 
moderate to strong discriminatory power. Next, adding the group without a CIDI assessment 
due to cognitive impairment to the group of subjects with a formal DSM-IV diagnosis, the AUC 
remained almost equal (0.86) for the PBA, but slightly decreased (0.86) using the UHDRS-b. The 
discriminatory power was therefore considered to be moderate and of similar strength for both 
rating scales in cognitively impaired subjects with Huntington’s disease.
Sensitivity and specificity of the PBA and UHDRS-b for the presence of DSM-IV psychopathology
The PBA demonstrated an optimal sensitivity and specificity (respectively 79% [95% confidence 
interval (CI): 61 - 97%] and 81% [95% CI: 74 - 88%]) for psychopathology according to  DSM-IV at 
a cut-off of 91 points for the total PBA score. The corresponding negative and positive predictive 
values were 96% [95% CI:  92  -  100%] and 40% [95% CI:  24  -  55%], respectively. The optimal  sensi- 
tivity and specificity of the UHDRS-b (respectively 79% [95% CI: 61 - 97%] and 84% [95% CI: 
78 - 91%]) was at a cut-off of 27 points for the total UHDRS-b score. The corresponding  negative and 
positive predictive values were 96% [95% CI: 93 - 100%] and 44% [95% CI: 27 - 61%],  respectively. 
Discussion
We showed that both high PBA and UHDRS-b scores corresponded with the presence of 
a  psychiatric disorder according to DSM-IV criteria as assessed with the CIDI. Importantly, 
 making use of caregiver information, subjects in whom formal assessment of DSM-IV diagnosis 
 according to the CIDI was impossible because of cognitive impairment also showed high PBA 
and UHDRS-b scores. This finding confirms the face validity of these instruments suggesting 
severe and frequent psychopathology in patients in advanced disease stage.
Our finding that assessment using the PBA and UHDRS-b with caregiver information, was able 
to encompass psychopathology in all disease stages of Huntington’s disease, is in line with the 
suggestions done by others.11,12 The use of formal DSM diagnosis, instead of a dimensional 
 measure, may explain why in some earlier studies the published rates of psychiatric disorders 
in the advanced stage of Huntington’s disease were relatively low compared to earlier disease 
stages. Especially in advanced stage of Huntington’s disease, when communication and insight 
may become so impaired that subjects are no longer able to express or to judge their symptoms, 
reported rates of psychiatric disorders appeared to decrease.9 In this stage, the PBA and the 
UHDRS-b may be particularly useful, since they include caregiver information. This contributes 
to a more accurate assessment of psychopathology than a patient assessment alone.
Furthermore, the PBA and the UHDRS-b showed similar psychometric performances, with 
 similar negative and positive predictive values. The positive predictive values were rather low, 
due to the relative high number of subjects in whom the CIDI assessment was not possible.
The PBA has already shown an interrater reliability of 0.82 for severity scores and 0.73 for 
 frequency scores.21 Although the UHDRS is widely used, we are not aware of any study on 
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the  interrater reliability of the UHDRS-b which is a possible limitation of our study. A  second 
 limitation is that we did not assess the degree of insight, next to cognitive functioning, whereas 
lack of insight may already have been present before severe cognitive impairment. This may have 
 compromised outcomes of the CIDI, since the use of the CIDI does not require  information of the 
caregivers. A third limitation is that there is no agreement on the concept of  psychopathology 
in patients with advanced neurodegenerative disorders. Consequently, high PBA and UHDRS- 
b scores may not represent the presence of DSM-IV disorders, though they indicate the  presence 
of psychopathology. Finally, the number of patients with a formal DSM diagnosis was rather 
small, and therefore our results should be confirmed in other larger and therefore international 
cohorts of Huntington’s disease patients.
Whereas the assessment of psychopathology in advanced stages of Huntington’s disease 
is  difficult, it may be even more difficult to measure the effectiveness of pharmacotherapy 
of neuropsychiatric symptoms. Still, monitoring the effect of a pharmacological treatment is 
 compulsory to avoid the use of various non-indicated psychotropic medications. In our study, a 
high percentage of the patients used different psychotropic medications, especially those with 
cognitive impairments. Although the high PBA and UHDRS-b scores among these patients seem 
to justify the use of psychotropic medication, medication interactions and side effects may at 
the same time worsen motor symptoms. Furthermore, despite the frequent use of psychotropic 
medication, neuropsychiatric symptoms were still highly prevalent in this group.
In conclusion, the use of dimensional rating scales allows for the assessment of psychopatho-
logy, and for regular evaluation of psychiatric pharmacotherapy, making use of information of 
patients, caregivers and clinical parameters. The PBA and the UHDRS-b are particularly useful in 
the advanced stage of Huntington’s disease being indicative for initiation and (dis)continuation 
of psychiatric pharmacotherapy.
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Objective: To study prevalence and clinical correlates of apathy in Huntington’s disease.
Method: Apathy was defined as an Apathy Scale (AS) score ≥ 14 points in 152 Huntington’s 
disease mutation carriers and 56 non-carriers. Correlates of apathy were analyzed cross- 
sectionally in mutation carriers using multivariable logistic regression analysis.
Results: Forty-nine (32%) Huntington’s disease mutation carriers showed apathy compared to 
none of the non-carriers. After exclusion of 10 depressed subjects, apathy was independently 
associated with male sex, worse global functioning and higher use of neuroleptics and benzo-
diazepines.
Conclusion: Next to being male and worse global functioning, use of psychotropic medication 
was associated with apathy in Huntington’s disease patients.
Introduction
Huntington’s disease is an autosomal dominant, neurodegenerative disorder resulting from 
an expanded trinucleotide cytosine-adenine-guanine (CAG) repeat (≥ 36 glutamines), coding 
for the mutant protein huntingtin on chromosome 4p16.3.1 Symptomatic treatment is  widely 
 available although no cure is possible. Clinical features of Huntington’s disease consist of 
 movement, neuropsychiatric, and cognitive disorders. Disease progression causes a decline of 
daily  functioning and patients ultimately become totally dependent on the help of others.
Apathy is a common neuropsychiatric feature of Huntington’s disease.2-4 Reported  prevalences 
of apathy in Huntington’s disease vary from 34% to 76%, depending on disease stages  examined 
and assessment methods used,5 and its prevalence and severity increase with disease 
 progression.6 Apathy has been described both as a symptom (i.e. of mood disorder, altered 
level of consciousness, or cognitive impairment), and as a syndrome.7,8 An apathy  syndrome is 
 defined as a disorder of motivation; with loss of or diminished goal-directed behavior,  cognitive 
activity, and/or emotion; as wells as functional impairments that are attributable to the 
 apathy.9,10  Clinically, apathy has been related to decline in activities of daily living (ADL) causing 
a great burden of disease and distress in caregivers,11 also after adjusting for the presence of 
motor and cognitive deficits.12,13
In the present study, we aimed to assess the prevalence of apathy in Huntington’s disease 
 mutation carriers and control non-carriers. Furthermore, we investigated sociodemographic, 
clinical and neuropsychiatric correlates of apathy comparing Huntington’s disease mutation 
 carriers with apathy to those without apathy.
Methods
Subjects
Between May 2004 and August 2006, Huntington’s disease mutation carriers were recruited 
from the out-patient departments of Neurology and Clinical Genetics of the Leiden University 
Medical Center, and from a regional nursing home. Subjects with a CAG repeat length of 36 or 
more repeats were considered positive for Huntington’s disease mutation carriership.
The design of the study has been described in detail elsewhere.14 In short, of 361 known  subjects, 
45 out-patients were untraceable, 17 subjects were excluded or were deceased, and 89 refused 
to participate because of various reasons. Fifty-six subjects appeared to be  non-carriers. After 
the assessment, two more subjects were excluded because of a missing motor score. Thus, 
152 Huntington’s disease mutation carriers and 56 non-carriers were included in the present 
 analysis. All subjects gave written informed consent. The study was approved by the Medical 




Apathy was assessed using the semi-structured Apathy Scale (AS) (Figure 1; Appendix C).15 
The AS is a modified version of the Apathy Evaluation Scale (AES),7 and consists of 14 questions 
read by the interviewer, measuring different features of apathy in the two weeks prior to the 
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interview. As patients with apathy often lack insight into their behavior, we also used caregivers’ 
information. The subject and his/her informant are provided with four possible answers: ‘not at 
all’, ‘slightly’, ‘some’, and ‘a lot’. The total score of the AS ranges from 0 - 42 points, with higher 
scores indicating greater apathy. The AS has shown good interrater reliability, good test-retest 
reliability, as well as high internal consistency in patients with Parkinson’s disease.15 We used 
an AS total score ≥ 14 points to characterize subjects as apathetic, and those scoring below this 
cut-off score as non-apathetic.15,16
Figure 1.  Apathy Scale, patient version
1. Are you interested in learning new things?
2. Does anything interest you?  
3. Does someone have to tell you what to do each day?
4. Are you concerned about your condition?
5. Are you indifferent to things?
6. Do you put much effort into things?
7. Are you always looking for something to do?
8. Do you have plans and goals for the future?
9. Do you have motivation?
10. Do you have energy for daily activities?
11. Are you unconcerned with many things?
12. Do you need a push to get started on things?
13. Are you neither happy nor sad, just in between, no matter what happens?
14. Would you consider yourself to be apathetic?
Scoring: 
Questions 1, 2, 4, 6-10 : Not at all = 3; Slightly = 2; Some = 1; A lot = 0
Questions 3, 5, 11-14: Not at all = 0; Slightly = 1; Some = 2; A lot = 3
© 2001, S.E. Starkstein
Dutch version: see Appendix C
Sociodemographic and clinical characteristics
Information on sociodemographic and clinical characteristics of mutation carriers and  controls 
was collected in a standardized manner. Global functioning was assessed with the Total 
 Functioning Capacity (TFC) scale of the Unified Huntington’s Disease Rating Scale (UHDRS).17 The 
TFC scale consists of five questions assessing employment, capacity to handle financial affairs, to 
manage domestic chores, to perform activities of daily living, and the care level provided (range 
0 - 13 points, lower scores indicate poorer functional abilities).18
Assessment of motor function
Neurological examination was done by a neurologist with experience in Huntington’s disease, 
blind for the genetic status of the subject and according to the motor section of the Unified 
Huntington’s Disease Rating Scale (UHDRS-m).17 The UHDRS-m consists of 15 items that are 
rated on a scale from 0 (normal) to 4 (severe) points. The total UHDRS-m score is the sum of all 
individual motor ratings (total score range 0 - 124 points; higher scores indicating worse motor 
performance).
The Confidence Level of the UHDRS-m was used to define subjects as pre-motor symptomatic 
(Confidence Level score = 0 or 1 points) or motor symptomatic (Confidence Level  score = 2 - 4 
points).
Assessment of depression
Because symptoms of apathy may overlap with depression, we assessed the presence of 
 depression (major depressive disorder and dysthymia) according to the criteria of the  Diagnostic 
Statistical Manual (DSM) of mental disorders, Version IV.19 Psychiatric assessment was done by 
a psychiatrist (EvD) or a trained research assistant under his supervision. Raters for psychiatric 
and cognitive function were informed about the genetic status of the subjects, because non-
disclosure could considerably influence subjects’ answering to questions about symptoms that 
are directly related to mutation carriership.
The Dutch translation of the computerized version of Composite International Diagnostic 
 Interview (CIDI, Version 2.1) was used to classify depression according to DSM-IV criteria.20 
The CIDI was not administered in subjects with score < 18 points on the Mini-Mental State 
 Examination (MMSE), since the CIDI cannot be reliably administered to patients with such a 
severe cognitive dysfunction. In these subjects the presence of a depression was assessed 
 clinically, based on the psychiatric examination, medical reports, and information of caregivers.
Neuropsychological assessment
The MMSE, Symbol Digit Modalities Test (SDMT), Verbal Fluency Test (VFT), and Stroop Color-
Word tests were administered to assess cognitive function. The MMSE consists of 11 items that 
has been found to be reliable and valid in assessing global cognitive function. Scoring range of 
the MMSE is 0 - 30 points with lower scores indicating worse global cognitive performance.21 
The SDMT examines attention, working memory, and visuoverbal substitution speed.22 Subjects 
have 90 seconds to write down the number that matches each of the geometric figures, which 
are printed on several lines. The VFT is sensitive to frontal executive dysfunction and subtle 
degrees of semantic memory impairment.23 Subjects are instructed to generate as many words 
as possible in one minute. A total VFT score of less than 30 words is considered abnormal. The 
Stroop Color-Word test was used to measure a person’s sustained attention in three conditions: 
color naming, word reading, and naming the color of the ink of an incongruous color name 
 (interference).24 For each condition the subject had 45 seconds and the total of all right answers 
was scored, with maximum 100 points per condition.
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Data are presented as n (%), mean (± SD) or median (interquartile range [IQR], i.e., 25th to 75th 
percentiles) when appropriate. χ2-Tests for categorical data, t-tests for independent  samples 
with normal distributions, or non-parametric Mann-Whitney U tests were conducted to  compare 
mutation carriers and non-carriers. Mutation carriers with and without apathy were compared 
to determine correlates of apathy using univariate logistic regression analyses. Odds ratio’s (OR) 
and their corresponding 95% confidence interval (CI) were computed. TFC,  UHDRS-m, MMSE, 
SDMT, VFT and Stroop Color-Word test scores were divided into two groups using a median split. 
A p value < 0.05 was considered statistically significant.
Because of a strong collinearity between the SDMT, VFT, and Stroop Color-Word test, a new va-
riable for executive cognitive function (ExCogn) was computed by averaging the 4 index z-scores 
(i.e., subtracting the mean from an individual raw score and then dividing the difference by the 
standard deviation).
Multiple logistic regression analysis, identified by a forward stepwise selection procedure, 
was used to determine the independent correlates of apathy. For this analysis, the following 
 variables with p < 0.05 in the univariate regression analysis were used: sex, age, TFC score, 
UHDRS-m score, use of antidepressants, use of neuroleptics, use of benzodiazepines, presence 
of depression, MMSE score, and ExCogn score. The overall use of psychotropic medication was 
not entered, because of the inclusion of the three medication subcategories.
Results
Sociodemographic and clinical characteristics of mutation carriers versus non-carriers
The sociodemographic, clinical, and neuropsychiatric characteristics of 152 Huntington’s disease 
mutation carriers and 56 non-carriers are shown in Table 1. Mutation carriers were older and 
had significantly more symptoms of apathy than non-carriers (Table 1). Mutation carriers also 
had more often a formal DSM-IV diagnosis of depression compared to non-carriers. Assessment 
of the CIDI was not possible in 12 mutation carriers because of severe cognitive impairment 
(MMSE < 18 points). Using information of caregivers, medical reports and clinical impression 
during the assessment, 2 of these 12 mutation carriers were diagnosed as depressed.
Mutation carriers with motor symptoms showed significantly more symptoms of apathy than 
pre-motor symptomatic mutation carriers and non-carriers, and pre-motor symptomatic 
 mutation carriers showed significantly more symptoms of apathy than non-carriers (all p < 0.05) 
(Figure 2).
Huntington’s disease mutation carriers with and without apathy
Forty-nine mutation carriers (32%) were considered apathetic (median AS score = 20 points; 
IQR = 16 - 27), whereas 103 mutation carriers (68%) were not (median AS score = 7 points; 
IQR = 3 - 10) (Table 2).
Univariate regression analysis showed that, in comparison with non-apathetic mutation  carriers, 
apathetic subjects were more often male and older, had a lower TFC score, a higher UHDRS-m 
total score, used more psychotropic medication, were diagnosed more often as depressed, and 
showed worse global and executive cognitive function.
Table 1. Sociodemographic, clinical, and neuropsychiatric characteristics of Huntington’s disease 
mutation carriers and non-carriers
 Mutation carriers Non-carriers p value ‡
 (n = 152) (n = 56)  
Sociodemographic and clinical characteristics   
Male gender (n, %) 68 (45%) 25 (45%)  1.00
Age (years ± SD) 47.2 ± 11.9 39.7 ± 11.2 < 0.001
Higher level of education a (n, %) 92 (61%) 42 (75%)  0.05
Married or with partner (n, %) 98 (65%) 46 (82%)  0.18
CAG repeats (number ± SD) 44.1 ± 3.1 21.0 ± 4.8 < 0.00
Neuropsychiatric characteristics
AS b (points, IQR) 10 (5 - 16) 4 (2 - 6) < 0.001
AS ≥ 14 (n, %) 49 (32%) 0 -
DSM-IV c depression (n, %) 8 (5%) 0 -
Data are presented as n (%), mean (± SD) or median (interquartile range [IQR]) when appropriate. ‡ P values by chi-square tests for categorical 
data, by t-test for independent samples with normal distributions, or non-parametric Mann-Whitney U tests.
a Higher level of education: ≥ 12 years of education. b AS = Apathy Scale. c DSM-IV = Diagnostic Statistical Manual of mental disorders, Version IV.
Figure 2. Box plot showing Apathy Scale scores of non-carriers, pre-motor symptomatic and 
motor symptomatic mutation carriers.
The line within the box represents the median; the boundaries of the box represent the inter-quartile range, while the error bars represent the 
10th and 90th percentile values. The three groups were significantly different with the non-parametric Kruskal-Wallis test  (overall p < 0.001), 
while all three  groups differed from the other groups in Mann-Whitney tests in 3 post-hoc comparisons between two groups (all p < 0.05).



















Overall P < 0.001
 
 
The line within the box represents the median; the boundaries of the box represent the inter-quartile range, while the error 
bars represent t e 10th and 90th percentile values. 
The three groups were significantly different with the non-parametric Kruskal-Wallis test (overall p < 0.001), while all three  
groups differed from the other groups in Mann-Whitney tests in 3 post-hoc comparisons between two groups (all p < 0.05).  
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Table 2. Sociodemographic, clinical, and neuropsychiatric characteristics as predictors of apathy 
in Huntington’s disease mutation carriers
 No apathy Apathy § Univariate  p value‡
 (n = 103) (n = 49) logistic   
   regression
   OR (95% CI)  
Sociodemographic characteristics    
Male (n, %) 40 (39%) 28 (57%) 2.10 (1.05-4.19) 0.04
Age (years ± SD) 45.5 ± 11.3 50.8 ± 12.3 1.04 (1.01-1.07) 0.01
Higher level of education (n, %) 66 (64%) 26 (53%) 0.62 (0.31-1.24) 0.18
Married or with partner (n, %) 35 (34%) 19 (39%) 1.23 (0.61-2.49) 0.56
    
Clinical characteristics    
CAG repeats (number ± SD) 44.0 ± 3.1 44.2 ± 3.2 1.02 (0.92-1.14) 0.71
TFC a [< 11 points] (n, %) 39 (38%) 37 (76%) 5.06 (2.36-10.9) < 0.001
UHDRS-m b [> 15 points] (n, %) 43 (42%) 36 (74%) 4.02 (1.91-8.48) < 0.001
Use of psychotropic medication (n, %) 27 (26%) 35 (71%) 7.04 (3.29-15.0) < 0.001
      - Antidepressants (n, %) 19 (18%) 24 (49%) 4.24 (2.01-8.98) < 0.001
      - Neuroleptics (n, %) 5 (5%) 13 (27%) 7.08 (2.36-21.3) < 0.001
      - Benzodiazepines (n, %) 14 (14%) 22 (45%) 5.18 (2.34-11.5) < 0.001
    
Neuropsychiatric characteristics    
AS c (points, IQR) 7 (3-10) 20 (16-27) -  < 0.001
DSM-IV d depression (n, %) 1 (1%) 7 (14%) 21.9 (2.59-184) < 0.001
MMSE e [< 27 points] (n, %) 49 (48%) 34 (69%) 2.60 (1.26-5.34) 0.01
SDMT f [< 34 points] (n, %) 41 (40%) 35 (71%) 3.78 (1.81-7.88) < 0.001
VFT g [< 19 points] (n, %) 42 (41%) 34 (69%) 3.29 (1.60-6.79) 0.001
Stroop-Color [< 50 points] (n, %) 41 (40%) 33 (67%) 3.12 (1.53-6.38) 0.002
Stroop-Word [< 72 points] (n, %) 40 (39%) 36 (74%) 4.36 (2.07-9.21) < 0.001
Stroop-Interference [< 29 points] (n, %) 41 (40%) 34 (69%) 3.43 (1.66-7.07) 0.001
ExCogn h [< 0.05] (n, %) 42 (41%) 34 (69%) 3.29 (1.60-6.79) 0.001
 
Data are n (%) or mean (± SD) when appropriate.
Odds ratio’s (OR) and the corresponding 95% confidence interval (CI) are provided.
§ Apathy was defined as an Apathy Scale score ≥ 14 points.
‡ P values by univariate logistic regression analysis, or non-parametric Mann-Whitney U tests.
a TFC = Total Functional Capacity; b UHDRS-m = Unified Huntington’s Disease Rating Scale, motor section; c AS = Apathy Scale; d DSM-IV = 
Diagnostic Statistical Manual of mental disorders, Version IV; e MMSE = Mini-Mental State Examination; f SDMT = Symbol Digit Modality Test; 
g VFT = Verbal Fluency Test; h ExCogn = executive cognitive function defined by 5 index z-scores derived from SDMT, VFT,  and Stroop tests).
TFC, UHDRS-m, MMSE, SDMT, VFT, Stroop tests, and ExCogn scores are divided into two groups using a median split. 
Independent correlates of apathy in Huntington’s disease mutation carriers
Using logistic regression analysis male sex, higher use of both antidepressants and neuroleptics, 
and the presence of depression were statistically significant independent correlates of apathy in 
a multivariable analysis (Table 3a).
In addition, a sensitivity analysis was conducted to evaluate the robustness of our model and 
to eliminate the possibility of confounding influences of depression on the correlates of apathy. 
As described above, eight subjects had a formal diagnosis of depression according to the CIDI 
(7 subjects in the apathetic group and 1 subject in the non-apathetic group), and 2 without 
the CIDI assessment were clinically depressed (both in the apathetic group). After exclusion of 
these 10 subjects with depression, higher use of antidepressants was no longer independently 
associated with the presence of apathy. However, male sex and higher use of neuroleptics were 
still independent predictors of apathy, together with lower TFC score, and higher use of benzo-
diazepines (Table 3b). 
Table 3a. Independent predictors of apathy in 49 Huntington’s disease mutation carriers
 No apathy Apathy p value ‡
 Reference OR (95% CI) 
 (n = 103) (n = 49)  
Male sex 1.00 2.46 (1.05 - 5.78) 0.04
Use of antidepressants 1.00 2.72 (1.13 - 6.55) 0.03
Use of neuroleptics  1.00 4.40 (1.20 - 16.1) 0.03
Depression 1.00 23.84 (2.40 - 237) 0.007
Table 3b. Independent predictors of apathy in 41 Huntington’s disease mutation carriers, after 
exclusion of 10 subjects with a depression
 No apathy Apathy p value ‡
 Reference OR (95% CI) 
 (n = 102) (n = 40)
Male sex 1.00 2.73 (1.15 - 6.50) 0.02
TFC score 1.00 2.88 (1.18 - 7.07) 0.02
Use of neuroleptics 1.00 3.64 (1.01 - 13.1) 0.048
Use of benzodiazepines 1.00 2.91 (1.07 - 7.86) 0.04
Odds ratio’s (OR) and the corresponding 95% confidence intervals (CI) are provided.
‡ P values by multivariate forward logistic regression.
TFC = Total Functional Capacity. 
88





The results of our study confirm that apathy frequently occurs in Huntington’s disease with a 
prevalence of 32% in mutation carriers compared to 0% in non-carriers. Mutation carriers with 
apathy were more likely to be male, of older age, and were using more psychotropic  medication. 
When comparing mutation carriers with apathy to those without apathy, significantly more 
depression, worse total functioning with more severe motor and cognitive symptoms, and 
 increased use of psychotropic medication was shown. After exclusion of mutation carriers with 
depression, the independent associations with the presence of apathy in Huntington’s disease 
mutation carriers were male sex, worse global functioning, higher use of neuroleptics, and 
 higher use of benzodiazepines.
Apathy and depression
The relationship between apathy and depression varies across diagnostic groups and  depends 
on assessment tools used.25 Apathy can be a clinical sign of depression, but can also occur 
 independently. In Huntington’s disease, apathy has been shown to be associated with the 
 presence of depressed mood,3 but inconsistently.11,26,27 Contrary to our findings, one other 
 study using the CIDI found no association between a formal diagnosis of depression and  apathy 
in patients with traumatic brain injury.28 In another study applying a factor analysis of the 
 Montgomery and Åsberg Depression Rating Scale (MADRS)29 in patients with acquired brain 
damage, ‘negative symptoms’ of depression were highly associated with apathy, whereas 
 ‘depressed mood’ or ‘somatic symptoms’ were not.30
Apathy and the use of psychotropic medication
The presence of apathy was associated with higher use of different types of  psychotropic 
 medication. The association with the use of antidepressants – not surprisingly –  disappeared 
 after the exclusion of subjects with depression. Higher use of neuroleptics remained 
 independently predictive, together with higher use of benzodiazepines. Since this study has 
a cross-sectional design, we cannot conclude whether the use of psychotropic medication is 
a cause or  consequence of apathy. In clinical practice, antidepressants may be prescribed as a 
 treatment for apathy, but in our study their use seems to be related to presence of  depression. 
Development of apathy as a side-effect of the use of neuroleptics and benzodiazepines is very 
well possible, due to their blunting and sedative effects, which may result in lethargy and  fatigue.
Furthermore, distinguishing apathy from depression is of clinical importance because of 
 potential differences in the use of pharmacological and non-pharmacological  interventions. 
 Pharmacotherapy for depression may improve the clinical profile, but can also have a 
 counteractive effect on apathy.31 For example, serotonin reuptake inhibitors may increase 
 apathy and withdrawal from engagement with the environment.32
To date, no specific treatments for apathy are known. Preliminary studies suggest that apathy 
may respond to pharmacotherapy with stimulants, dopamine agonists, acetylcholinesterase 
 inhibitors, or NMDA-receptor antagonists.33,34
Apathy and cognitive function
Using univariate analysis we found an association between presence of apathy and  worse 
 cognitive function. This result is in line with a previous study among patients with early 
 Huntington’s disease, that found severe deficits in attention, executive function, and  episodic 
memory to be related to apathy.35 In other neurodegenerative disorders, an association 
between apathy and cognitive dysfunction has also been described. For example, apathy 
 correlated with initiation-perseveration in subjects with progressive supranuclear palsy,36 and 
a  correlation between apathy and worse performance on several cognitive tests among which 
executive  cognitive function in Parkinson’s disease has been reported.27 Also, in Alzheimer’s 
disease,  patients with apathy performed worse on the SDMT and the Stroop-Interference 
test, than those without apathy.37 In patients with dementia and apathy, a faster cognitive and 
 functional decline has been found compared to patients without apathy.34 In an earlier study,6 
we found significantly more apathy in advanced disease stage. Therefore, apathy may be a 
sign of disease progression in  Huntington’s disease, including progressive motor and cognitive 
 impairments, and worse global functioning, but longitudinal studies are needed to investigate 
precise  relationships.
The strengths of this study are a relatively large study population with Huntington’s disease, 
the use of a comparison group, and the use of specific and validated measurement tools in 
a  standardized interview. However, there are some limitations that warrant discussion. First, 
this study involved the analysis of cross-sectional data which precludes conclusions about the 
 direction of causality. Second, as discussed before, assessment of the AS was done during a 
clinical interview with the mutation carrier and an informant, whereas the CIDI was  assessed 
in absence of the informant. This may have reduced the validity of the CIDI  assessment, 
as  Huntington’s disease patients may have a lack of insight into their own behavior and 
 feelings.  Another  limitation was that some of the explanatory variables were rather strongly 
 intercorrelated and that the automated variable selection method in the logistic regression may 
therefore have produced models of somewhat limited stability. Further, all subjects volunteered 
to participate in this study, which may have led to an underestimation of the prevalence of 
 apathy in Huntington’s disease patients due to selection bias, as subjects who did not respond 
to the invitation to participate in the study may have been more apathetic. 
We conclude that apathy is highly prevalent in Huntington’s disease and is strongly  associated 
with the presence of depression, worse global functioning, and the use of psychotropic 
 medication (especially neuroleptics and benzodiazepines). Therefore, we advise to evaluate the 
use of all psychotropic medications to exclude an iatrogenic cause of apathy. 
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Neurodegeneration in Huntington’s disease occurs in various brain regions including the 
 hypothalamus. In this cross-sectional study, hypothalamic-pituitary-adrenal axis functioning 
was studied in 26 presymptomatic and 58 symptomatic Huntington’s disease mutation  carriers, 
and 28 controls. Hypothalamic-pituitary-adrenal axis functioning was measured through 
 salivary cortisol in the day curve, the cortisol awakening response (CAR), the area under the 
curve (AUC), the morning rise, and the dexamethasone suppression test (DST).The CAR was 
statistically  different (p = 0.046) between the three groups, being explained by higher cortisol 
 concentrations at 45 and 60 minutes post-awakening for presymptomatic mutation carriers 
compared to both symptomatic mutation carriers and controls. The morning rise was also 
 higher for presymptomatic mutation carriers (p = 0.005). No differences were found for the 
AUC, evening and post-DST cortisol concentrations. Our study indicates a delicate disturbance 
in morning cortisol secretion in Huntington’s disease mutation carriers that precedes the onset 
of motor symptoms. 
Introduction
Huntington’s disease is a progressive autosomal dominant neurodegenerative disorder 
 characterized by motor symptoms, cognitive decline, behavioral problems and psychia-
tric  disorders.1 Huntington’s disease is caused by a trinucleotide expansion on chromosome 
4 (4p16.3), coding for the mutant protein huntingtin.2 Neurodegeneration primarily occurs 
in the striatum and cerebral cortex. Atrophy has also been found in hypothalamic areas,3,4 
with  neuronal loss up to 90% in the nucleus tuberalis lateralis.5,6 Direct involvement of 
 huntingtin and  pathological mechanisms, such as decreased hypocretin neurotransmission,7 
loss of  hypothalamic D2 receptors and microglia activation,
8 may play a role in hypothalamic 
 dysfunctioning in Huntington’s disease. Consequently, malfunctioning of the hypothalamic- 
pituitary-adrenal axis might occur.9
The hypothalamic-pituitary-adrenal axis regulates the stress response.10 Corticotropin- releasing 
hormone, being released in a circadian, pulsatile rhythm in the hypothalamus with an in-
crease in amplitude in the early morning hours, stimulates the anterior pituitary to produce 
 adrenocorticotropic hormone that triggers the secretion of glucocorticoids from the adrenal 
cortex.
Previous studies have reported a hyperactivation of the hypothalamic-pituitary-adrenal axis in 
mutation carriers with increased corticotropin-releasing hormone in cerebrospinal fluid (CSF),11 
and increased cortisol concentrations in plasma,12.13 and urine.14 However, none of these 
 studies, except for one,12 took into account the circadian rhythm of the hypothalamic-pituitary-
adrenal axis. Sample sizes varied from 10 to 82 Huntington’s disease mutation carriers, while 
potential confounders of the hypothalamic-pituitary-adrenal axis were inconsistently taken 
into account. Our study therefore aimed to investigate the functioning of the hypothalamic-
pituitary-adrenal axis as assessed with a cortisol day curve and dexamethasone suppression test 




All 210 participating subjects (154 Huntington’s disease mutation carriers and 56 controls) of 
an ongoing follow-up study on behavioral problems and psychiatric disorders in Huntington’s 
disease,15 were invited to participate. These persons had been recruited at the start of the 
study from the outpatient clinics of Neurology and Clinical Genetics of the Leiden University 
Medical Center, a nursing home with a specialized ward for Huntington’s disease patients and 
the Dutch Huntington’s disease patients association. Verified non-carriers with a CAG repeat 
< 36 were included as a control group because they had been exposed to the same stressful 
family circumstances as mutation carriers. Severely dysarthric and mutistic patients were 
 excluded, as well as patients with juvenile onset Huntington’s disease, concurrent diseases of 
the central nervous system or an insufficient command of the Dutch language. All subjects were 
Caucasian.
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Twenty-five subjects refused to participate in this follow-up study, four subjects were untrace-
able, two were deceased, and one subject had become too severely affected to communicate. 
The remaining 178 subjects participated in this part of the study. The study was approved by the 
Medical Ethical Committee of the Leiden University Medical Center and all subjects gave their 
informed consent.
Demographic and clinical characteristics
Demographic and clinical characteristics, including potential confounders for hypothalamic-
pituitary-adrenal axis functioning, like sex, age, smoking status, high alcohol consumption 
(> 14 consumptions a week), body mass index (BMI), presence of depressive disorder, and use 
of corticosteroid and psychotropic medication were assessed during a standardized interview. In 
addition, global cognitive functioning and general functioning were measured.
The presence of a depressive disorder (major depressive or dysthymic disorder) in the past two 
weeks was assessed with the Composite International Diagnostic Interview (CIDI),  computerized 
version 2.1.16 The CIDI is a fully structured psychiatric interview for disease classification of 
psychiatric disorders according to the Diagnostic and Statistical Manual of mental disorders 
(DSM).17 Global cognitive functioning was measured using the Mini-Mental State Examination 
(MMSE).18 Because of lack of reliability in subjects with severe cognitive dysfunction, the CIDI 
was not administered to subjects with a MMSE score < 18 points. Global general functioning 
was assessed using the Total Functioning Capacity (TFC) of the Unified Huntington’s Disease 
Rating Scale (UHDRS).19 The TFC consists of 5 questions assessing employment, the capacity 
to handle financial affairs, to manage domestic chores, to perform activities of daily living, and 
the care level provided. The TFC ranges from 0 - 13 points, with lower scores indicating poorer 
functional abilities.20
Assessment of motor functioning and disease stage
Subjects were examined for assessment of motor symptoms by a neurologist with experience 
of Huntington’s disease using the motor section of the UHDRS. The neurologist was blinded to 
the genetic status of the subjects and the results of all other assessments. Based on the clinical 
examination, the neurologist assigned a score indicating to what degree he was confident that 
the presence of an extrapyramidal movement disorder in a subject might be due to  Huntington’s 
disease. Mutation carriers with confidence level score 0 (normal) or 1 (nonspecific motor 
 abnormalities; < 50% confidence) were considered presymptomatic (n = 26). The remaining 
mutation carriers (n = 58) with score 2 (motor abnormalities that may be signs of Huntington’s 
disease; 50 - 89% confidence), 3 (likely signs of Huntington’s disease; 90 - 98% confidence), or 
4 (unequivocal signs of Huntington’s disease; ≥ 99% confidence) were considered symptomatic.
Measurement of hypothalamic-pituitary-adrenal axis functioning
Functioning of the hypothalamic-pituitary-adrenal axis was assessed by the use of cortisol 
 concentrations in saliva, reflecting the free fraction of plasma cortisol.21 Advantages of salivary 
cortisol above plasma cortisol measurement are the easy collection of saliva by the subjects at 
their homes, the possibility of repeated sampling to yield a day curve, the stability of cortisol 
at room temperature during the time required for this study, the absence of stress induction 
by a venapuncture, and the lower costs.22 After oral and written instruction, subjects were as-
ked to collect saliva by themselves on two consecutive days. For this, they had to place cotton 
wads from a saliva collection tube (Salivette; Sarstedt, Newton, NC) in their mouth and chew 
on them until they were saturated. The wads were restored in the tube labeled with date and 
time.  Subjects were asked to refrain from eating, drinking, and brushing their teeth before the 
morning sampling to avoid contamination of the saliva with food or blood. They were free to 
wake up according to their normal schedule, but were asked to record their time of awakening 
because the cortisol response may be influenced by the time of awakening.22
The circadian rhythm of the hypothalamic-pituitary-adrenal axis was taken into account by 
 assessing a cortisol day curve. On day 1 six samples were taken: at the time of awakening, 30, 
45, and 60 minutes post-awakening, at 22:00 h, and at 23:00 h. The cortisol awakening response 
(CAR) is a distinctive measurement of the cortisol circadian cycle. In healthy adults salivary 
 cortisol concentrations increase by 50% to 160% in the first 30 minutes post-awakening.23 The 
CAR is defined as the mean of the two cortisol concentrations at 45 minutes and at 60 minutes 
post-awakening, minus the cortisol concentration at the time of awakening on day 1.24 The area 
under the curve (AUC) with respect to ground was calculated according to the trapezoid formula 
using the first four time points.25
The DST is a measure of hypothalamic-pituitary-adrenal axis regulation and normally shows a 
decrease of morning cortisol concentrations due to inhibition of adrenocorticotropic hormone 
secretion after dexamethasone administration the night before.26 A low dose of  dexamethasone 
(0.5 mg) had to be taken orally after the last sample on day 1, and the final sample was  taken 
at the time of awakening on day 2. After collecting all seven samples, the subjects were  asked 
to return the tubes through regular postal service. After centrifugation of the cotton wad, 
 salivary cortisol concentrations were measured with a competitive  electrochemiluminescence 
 immuneassay (ECLIA), using a Modular Analytics E170 immunoassay analyzer (Roche  Diagnostics, 
Mannheim, Germany) by the Central Laboratory for Clinical Chemistry of the Leiden University 
Medical  Center. The functional detection limit was 2.0 nmol/l and the intra- and inter-assay 
variability coefficients in the measuring range were less than 10%. We assumed concentrations 
≥ 100 nmol/l to be physiologically unlikely.
Statistical analyses
Categorical variables are presented as numbers and percentages, and continuous variables 
as means ± standard deviations (SD) or medians with percentiles P10 - P90, when appropriate. 
 Differences between the three groups were assessed by one-way analysis of variance  (ANOVA). 
Post-hoc intergroup comparisons were performed for those variables with significant test 
 results. All subjects with four or more missing salivary cortisol concentrations on day 1 were 
excluded (n = 5). All other missing cortisol data (n = 21 of 672; 3.1%) were intrapolated by using 
the subject’s preceding and following salivary cortisol values, and modeling the average curve 
from all subjects over these values for that point in time. For positively skewed variables, na-
tural log-transformed values were used in statistical analyses, and back-transformed geometric 
mean values are presented in tables. The cortisol awakening response (CAR) was analyzed by 
 repeated measurements general linear models (GLM), with time as within-subject factor and 
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group as between-subject factor. Next, three markers of salivary cortisol were calculated. The 
total area under the curve of the morning rise (AUC) was calculated using trapezoid formula. 
The morning rise during the CAR was calculated as the maximum of the two cortisol concentra-
tions at 30  minutes and at 45 minutes post-awakening, minus the cortisol concentration at time 
of  awakening on day 1. The cortisol suppression ratio was calculated as the salivary cortisol at 
the time of awakening on the first day / post-DST salivary cortisol. Differences in cortisol levels 
and markers between the three groups were assessed by ANOVA. The covariates sex, age, the 
use of psychotropic medication, and the time of awaking were added to multivariable models 
using ANOVA, to adjust for potential confounding effects. Significance levels were set at p < 
0.05. Statistical analysis was performed using the Statistical Package for the Social Sciences 16.0 
for Windows.
Results
Demographic and clinical characteristics
Forty subjects (22%) declined saliva collection, 24 subjects (13%) collected insufficient saliva, 
and two subjects (1%) were excluded because of physiologically unlikely high salivary cortisol 
concentrations. One subject was excluded because of the use of oral corticosteroid  medication 
at the time of the study. None of the female subjects reported pregnancy, that potentially 
may affect cortisol concentrations. This resulted in available saliva of 58 symptomatic and 26 
 presymptomatic mutation carriers, and 28 controls. Demographic and clinical characteristics of 
these subjects are presented in Table 1; as is shown, data of the potential confounders  smoking 
status, alcohol consumption, BMI, and use of psychotropic medication were  incomplete. Further, 
the presence of a depressive disorder could not be assessed in five symptomatic  mutation 
 carriers because of a MMSE score < 18 points.Hypothalamic-pituitary-adrenal axis functioning
Since we assumed cortisol concentrations ≥ 100 nmol/l to be physiologically unlikely, 
 measurements at seven time points (1.0%) of a total of 672 measurements in 112 subjects were 
excluded.
On day 1, using repeated measurements GLM there was a time effect for the CAR (p < 0.001, 
indicating an increase at 30 minutes post-awakening), a time * group effect (p = 0.04,  indicating 
that the dynamics of the curve were dissimilar between the groups), and a group effect 
(p = 0.046). Post-hoc tests showed that the mean cortisol concentration of the presymp-
tomatic  mutation carriers was higher compared to the symptomatic mutation carriers 
(p = 0.035),  largely due to higher mean cortisol concentrations at 45 minutes and 60 minutes 
post-awakening  (Table 2 and Figure 1). For the mean evening cortisol concentrations there was 
no time effect (p = 0.29), no time * group effect (p = 0.95), and no group effect (p = 0.21). The 
AUC showed a trend towards significance (p = 0.09).
On day 2, using ANOVA after the DST, there were no statistically significant differences between 
the groups for morning salivary cortisol concentrations (p = 0.39) nor for the cortisol suppres-
sion ratio (p = 0.92) (Table 2).
Effect of potential confounders
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of depression. Therefore, we did not adjust for these variables as potential confounders in 
 subsequent multivariable models. However, a significant difference between the three groups 
was found for age, use of psychotropic medication and time of awakening, which may have had 
influenced cortisol concentrations. Symptomatic mutation carriers woke up later than controls 
(7:52 ± 1:22 h versus 7:07 ± 1:06 h; p = 0.03), whereas the presymptomatic group woke up in 
between (7:22 ± 1:02 h). After adjustment for age, sex, psychotropic medication and the time 
of awakening, the morning rise during the CAR between the three groups was still significantly 
different (p  = 0.005). The AUC between the three groups however was not significantly different 
(p = 0.12; Table 2). Moreover, after exclusion of subjects with time of awakening after 9:00 h, 
the morning rise during the CAR still showed a statistical trend of being different between the 
three groups (p = 0.07). 
Figure 1. Salivary cortisol concentrations of the day curve and post-DST
Panel A shows the basal salivary concentrations of day 1 on a logarithmic scale. Panel B shows the post-dexamethasone suppression test (DST) 
cortisol concentrations of day 2 on a logarithmic scale.
* Mean cortisol concentrations at 45 and 60 minutes after time of awakening in presymptomatic Huntington’s disease mutation carriers were 
significantly higher, compared to non-carriers, as well as compared to symptomatic mutation carriers.
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The differences in the CAR of the three study groups were explained by higher salivary 
 cortisol concentrations at 45 and 60 minutes post-awakening and a higher morning rise for 
 presymptomatic mutation carriers compared to both symptomatic mutation carriers and 
 controls. These differences persisted after adjustment for potential confounders.
Increased basal plasma cortisol concentrations have previously been reported in two small 
 studies including only 10,12 and 11 symptomatic Huntington’s disease patients,13 whereas 
no  difference was found in a single morning sample between 8:00 h and 10:00 h in a study 
 comparing 41 symptomatic and 18 presymptomatic female Huntington’s disease mutation 
 carriers as well as healthy controls.27 Similar to our findings, no significant difference was 
found for post-DST cortisol concentrations between 10 Huntington’s disease patients and 10 
controls.12 In a large study among 82 moderate and advanced Huntington’s disease mutation 
carriers,  higher urinary cortisol concentrations have been described, compared to 68 healthy 
controls.14 However, in the latter study, measurement of cortisol concentrations was done in 
urine samples that were  collected during a short time period (between 14:00 and 17:00 h), 
and disease stage was  defined according to the TFC instead of the motor section of the UHDRS. 
Thus, except for one small study,12 the circadian rhythm was not taken into account.  Moreover, 
 potential  confounders of hypothalamic-pituitary-adrenal axis functioning such as smoking 
 status, alcohol  consumption, BMI, use of psychotropic medication and presence of  depression, 
was  inconsistently adjusted for in the four studies that examined hypothalamic-pituitary- adrenal 
axis functioning in  Huntington’s disease.
Different hypotheses exist concerning hyperactivation of the hypothalamic-pituitary- adrenal 
axis in Huntington’s disease. First, psychosocial life stress from growing up in  families with 
 members suffering from Huntington’s disease might induce chronic hypothalamic- pituitary-
adrenal axis  hyperactivation. Second, following disclosure of being mutation carrier, 
 presymptomatic  mutation carriers may experience stress due to continuous self-observation for 
the onset of symptoms, causing hyperactivity of the hypothalamic-pituitary-adrenal axis. Third, 
 hyperactivation of the hypothalamic-pituitary-adrenal axis could be the result of  hypothalamic 
degeneration disrupting its delicate feedback mechanisms.9 Fourth, degeneration of the 
 hippocampus and the frontal cortex in Huntington’s disease may indirectly cause a diminished 
feedback inhibition of the hypothalamic-pituitary-adrenal axis, leading to hyperactivation.28 
There are indications that increased cortisol concentrations may cause further degeneration of 
the hippocampus.29,30 Fifth, it has been suggested that the loss of GABA neurons in Huntington’s 
disease induces an endogenous corticotropin-releasing hormone overdrive, resulting in higher 
cortisol levels.11 Also, increased cortisol concentrations may in turn contribute to an increased 
susceptibility for emotional disturbances, which may further induce hypothalamic-pituitary-
adrenal axis activity.31
These hypotheses would lead one to expect a further hyperactivation of the hypothalamic-
pituitary-adrenal axis during disease progression, but this is not supported by the data from 
our cross-sectional study. In contrary to an earlier report,14 we found diminished activation of 
the hypothalamic-pituitary-adrenal axis in subjects with prevalent motor symptoms reflecting 
more advanced disease stage. In our opinion, this might be the result of either decreased 
 responsiveness or exhaustion of the hypothalamic-pituitary-adrenal axis, which is supported 
by a postmortem study that reported a decreased concentration of corticotropin-releasing 
 hormone immunoreactivity in the striatum of 11 Huntington’s disease patients.32
Alternatively, the impact of psychosocial stress may be reduced once the disease is  clinically 
 manifest, as a result of the acceptance of the disease, whereas in advanced disease stage, 
 subjects may have a diminished awareness of current stress factors.
Several limitations of the present study need to be addressed. First, the data are cross-sectional, 
and therefore do not allow for causal inferences. Second, the saliva collection was unsupervised; 
to improve compliance with respect to the time instructions, controlled collection using devices 
with electronic time registration is advised but expensive. Also, some subjects in an advanced 
stage of the disease had difficulties in collecting sufficient saliva, possibly as a result of disturbed 
osmoregulation or impaired saliva production in Huntington’s disease.33 Third, missing cortisol 
concentrations were intrapolated, but potential effect of bias is likely to be small as only 3% of 
time points were missing. Fourth, disease stage was defined according to the confidence level of 
the motor section of the UHDRS that depends on the experience and knowledge of the clinician, 
and solely assesses the presence of motor symptoms. Finally, we found differences between the 
groups for the CAR, but it is unclear whether other exogenous factors such as season, day of the 
week and sleep regulation have confounded this association.
Despite these shortcomings our study indicates a delicate disturbance in morning cortisol 
 secretion in Huntington’s disease mutation carriers that precedes the onset of motor symptoms, 
and possibly plays a role in the progression of the disease. Hyperactivity of the hypothalamic-
pituitary-adrenal axis may play a role in the development of the first subtle symptoms of 
 Huntington’s disease, including psychiatric phenomena. The use of more refined rating scales 
might increase our insight into a potential relationship between hypothalamic-pituitary-adrenal 
axis activation and the early manifestation of Huntington’s disease. 
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This thesis confirms that psychiatric disorders and behavioral problems are major  constituents 
of the clinical spectrum of Huntington’s disease. The prevalence of the different  psychiatric 
 disorders and behavioral problems vary, but overall mutation carriers are at major risk of 
 developing psychiatric disorders and behavioral problems in all disease stages. This is an 
 important finding because the presence of psychopathology has a substantial negative  impact 
on quality of life and daily functioning of patients, possibly even more so than motor and 
 cognitive symptoms.1
Assessment
In our review, we demonstrated that prevalences of psychiatric disorders and  behavioral  problems 
in Huntington’s disease depend on definition of the disease stages and the  measurement tools 
applied.
Definition of disease stages
In this thesis, the motor section of the Unified Huntington’s Disease Rating Scale (UHDRS-m) was 
used for the definition of disease stages.2 Although the motor score does not correlate  perfectly 
with disease stage, the use of a functional assessment (e.g., the Total Functional  Capacity 
(TFC)3 scale of the UHDRS) for disease staging was not preferable in our study, as it is directly 
 influenced by the presence of psychiatric disorders and behavioral problems.4 For that reason, 
we assume that the assessment of motor function by a blinded experienced neurologist is the 
most  objective and reliable method of disease staging for psychiatric research in  Huntington’s 
disease.
Measurement tools
Diagnostic classification according to the Diagnostic Statistical Manual of mental disorders, 
 Version IV (DSM-IV),5 is currently the gold standard for assessing psychiatric disorders in  general 
psychiatry. Yet, this diagnostic classification insufficiently takes into account co-morbid and 
overlapping physical symptoms of Huntington’s disease. Furthermore, cognitive impairments 
may complicate the assessment of a psychiatric diagnosis. Particularly in an advanced stage of 
Huntington’s disease, when communication and insight may become so impaired that  patients 
are no longer able to express their emotions or to judge their symptoms correctly.  Therefore, a 
structured interview using formal DSM-IV criteria seems less applicable in an advanced stage, 
since it will result in an underestimation of the prevalences of psychiatric disorders.6 In this 
 stage, dimensional measures of neuropsychiatric symptoms are necessary to capture the full 
range of psychopathology in Huntington’s disease. The semi-structured Problem  Behaviors 
 Assessment (PBA) is especially useful, since other diagnostic information sources such as 
clinician`s  observation of behavior and caregivers’ information are being used.7
Symptomatology
Both with the Composite International Diagnostic Interview (CIDI),8 assessing DSM-IV  diagnoses, 
and the PBA, assessing neuropsychiatric behavioral problems, an increased prevalence of 
 depression was found in mutation carriers. Despite a threefold increase of formal depression in 
the group of mutation carriers (18%) compared to the general population (6%), this prevalence is 
considerably lower than the 33% to 69% prevalences reported in earlier studies in  Huntington’s 
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disease.9-14 This can be explained by the fact that most earlier studies measured symptoms of 
depression such as ‘low mood’ or ‘dysphoria’, and not major depressive disorder meeting formal 
DSM-IV criteria. Also, some studies assessed the prevalence of psychiatric symptoms during 
a longer time period, e.g., prevalence since the occurrence of motor symptoms or life time 
 prevalence.
Depression is equally present in presymptomatic and symptomatic disease stages, as assessed 
with the CIDI, as well as with the PBA. The difference in prevalence of depression between 
presymptomatic mutation carriers and non-carriers did not reach statistical significance when 
formal DSM-IV criteria were used. However, using the PBA, we found a significant increase of 
depression in presymptomatic carriers compared to non-carriers. This could be a reflection of 
higher sensitivity of the PBA for depression in Huntington’s disease, but may also be due to 
increased power as the PBA is a continuous measure whereas the CIDI is not.
Apathy is also a common neuropsychiatric behavioral problem in Huntington’s disease, with 
 prevalences varying from 34% to 76%.9,10,14 Of all psychiatric symptoms, only apathy  consistently 
appears to be positively related to disease progression.14 In our study, using the Apathy Scale, 
32% of all mutation carriers showed apathy in the previous two weeks, compared to none of 
the non-carriers. We found that male sex was independently associated with apathy, together 
with higher use of both antidepressants and neuroleptics, and the presence of depression. As 
apathy may be an expression of depression, we excluded all subjects with depression (n = 10). 
Then, male sex, higher use of neuroleptics, higher use of benzodiazepines, and a decline of 
everyday functioning – that was quantified with the TFC scale – were independently associated 
with apathy. Since this study has a cross-sectional design, we cannot conclude whether the use 
of psychotropic medication is a cause or a consequence of apathy, but it is plausible that the use 
of psychotropic medication may at least worsen apathy.
In earlier studies increased prevalences of anxiety (34% - 61%) have been reported,9,10,12-14 
with higher prevalences in studies that used general questions about anxiety, worrying, and 
tensed feelings. In this thesis, we report a non-significant trend of an increased prevalence 
of  generalized anxiety disorder in Huntington’s disease. We also found a twofold increased 
 prevalence of panic disorder in mutation carriers, compared to the general population, but 
this difference was – presumably due to small numbers – non-significant. Factor analysis of the 
PBA revealed that anxiety and tensed feelings often co-occur with  depressed mood, depressed 
 cognitions and suicidal ideation, and may therefore be a symptom of an affective syndrome 
in Huntington’s disease, that is not covered by one DSM-IV diagnosis. Since no other studies 
are known that systematically investigated the prevalence of anxiety  disorders in Huntington’s 
disease, this should be an important focus for future research.
Many patients with Huntington’s disease show personality changes with obsessive-like  mental 
inflexibility in an early disease stage,15 though only a minority will get a formal diagnosis of 
obsessive-compulsive disorder. The few studies investigating obsessions and  compulsions in 
 verified mutation carriers, reported prevalences of 10% to 52% for the presence of  obsessive 
or compulsive symptoms.13-15 We found a significantly increased prevalence of formal 
 obsessive-compulsive disorder in  mutation carriers compared to the general population, both 
in presymptomatic (6%) and in symptomatic (4%) mutation carriers, although their numbers 
were small.
Irritability occurs in most patients with Huntington’s disease, and may also precede motor 
symptoms.9,10,12,14 We found an increased prevalence of irritability according to the PBA in 
 mutation carriers, compared to non-carriers, whereas no significant differences were found 
between disease stages. Given that irritability is a frequent neuropsychiatric symptom, 
 consensus on a distinct definition is warranted for the assessment and clinical follow-up during 
treatments.
Prevalences of psychotic symptoms in verified mutation carriers vary from 3% to 11%.9,10,12,14 
 However, we found only two mutation carriers (1%) with psychosis. Although it may be  delicate 
to draw conclusions from this small number of affected patients, the prevalence of psychosis 
may have been overestimated in earlier days when psychosis was considered to be a more 
 prevalent psychiatric feature of Huntington’s disease. Next to the use of strict DSM-IV  criteria, 
this can be explained by the relatively advanced disease stage at the time of diagnosis  before 
genetic testing became available. In fact, our two psychotic patients were also advanced 
 symptomatic patients.
Environmental and biological factors
Although family members with a prior 50% risk of Huntington’s disease, who were not  genetically 
compromised, had a shared environment during two to three decades of their lives, they had 
no more psychiatric disorders than the general population. In contrast to our assumption, 
the  presence of a familial disease burden, did not make them more susceptible to psychiatric 
 disorders than the general population.
It is unlikely that the mutation on its own has a full penetrance for the presence of psychiatric 
disorders; other factors probably contribute to the risk of developing psychopathology. Future 
research should focus on the contribution of both environmental and biological factors to the 
presence of psychopathology, that may enable early (preventive) interventions.
In this thesis, we examined the function of the hypothalamic-pituitary-adrenal axis in  mutation 
carriers and controls. The hypothalamic-pituitary-adrenal axis function was measured through 
salivary cortisol in a day curve and after a dexamethasone suppression test. We found an 
 increased salivary cortisol concentration in pre-motor symptomatic mutation carriers,  indicating 
a hyperactivation of the hypothalamic-pituitary-adrenal axis in mutation carriers before the 
 onset of motor symptoms. Increased cortisol concentrations may in turn contribute to an 
 increased susceptibility for emotional disturbances, but we could not demonstrate this in our 
cross-sectional study.
Strengths and weaknesses
The strengths of this study are the rather large study population with Huntington’s disease, 
the use of a control group consisting of mutation-negative first-degree relatives, and the use of 
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 specific, reliable and validated measurement tools in a standardized interview setting.
Some potential sources of variation in test results as found in our study, such as low incidence 
of Huntington’s disease with resulting small sample sizes and self-selection for testing and 
 research, were difficult to avoid. Also, since this is a cross-sectional and first assessment of a 
follow-up study, no conclusions can be drawn on changes in time or causal relations.
A weakness of our study is that many patients in mid and advanced disease stages used psycho-
tropic medications. A medication-free population would have been better for the assessment of 
psychopathology, though it is nearly impossible to include patients in these disease stages who 
do not use psychotropic medications. This may have confounded our results, with most likely 
an overestimation of apathy due to the use of neuroleptics and benzodiazepines, and an under-
estimation of other psychopathology.
Final remarks
This thesis confirms the observation of George Huntington that there is ‘a tendency to  insanity’ 
in Huntington’s disease,16 characterized by a variety of psychopathology, already before the 
 onset of motor symptoms. These psychiatric manifestations of Huntington’s disease have major 
influences on the daily functioning of patients and the lifes of caregivers.
Since recognition and treatment of psychopathology is often complicated by co-morbid  cognitive 
and motor symptoms, a multidisciplinary approach is recommended to provide the optimal 
patient care. Then, collaboration between clinical and pre-clinical researchers  is  needed for 
further research involving multiple disciplines, to bridge the gap between promising basic 
 research and solutions for clinical manifestations of Huntingtons’s disease. 
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This thesis starts with a review of original research on psychopathology in Huntington’s disease 
that used standardized instruments in verified mutation carriers (Chapter 2). Frequently 
 reported neuropsychiatric symptoms are depressed mood, apathy, anxiety, obsessive and 
 compulsive symptoms, irritability, and psychosis. However, many studies are hampered by small 
sample sizes and the lack of a control group, whereas different methodologies had been used.
Between May 2004 and August 2006, we started a large cohort study to assess psychopathology 
in verified Huntington’s disease mutation carriers in different disease stages, in comparison with 
first-degree non-carriers and the general population. 
Twenty-five percent of all mutation carriers had at least one formal psychiatric disorder 
 according to the Diagnostic Statistical Manual of mental disorders, Version IV (DSM-IV), with a 
significantly increased prevalence of depression, obsessive-compulsive disorder, and psychosis. 
Although first-degree non-carriers grew up in comparable, potentially stressful circumstances, 
they did not show more psychiatric disorders than the general population (Chapter 3).
Besides a formal diagnostic classification using the criteria of the DSM-IV, the prevalences of 
behavioral problems were assessed with the Problem Behaviors Assessment (PBA), that has 
 especially been developed for the assessment of behavioral problems in Huntington’s disease. 
After a factor analysis, the PBA showed a three factor solution: apathy, depression and  irritability. 
Apathy was related to disease stage, whereas depression and irritability were not (Chapter 4).
The use of general diagnostic criteria for the assessment of psychopathology in Huntington’s 
disease is complicated when co-morbid and overlapping physical and cognitive symptoms, or 
 diminished disease awareness are present. Since the PBA and the behavioral section of the 
 Unified Huntington’s Disease Rating Scale (UHDRS-b) use observation of behavior and  caregivers’ 
information, these instruments allow for the assessment of psychopathology in advanced stages 
of Huntington’s disease (Chapter 5). 
Of the mutation carriers forty-nine (32%) showed apathy, compared to none of the non- 
carriers. After exclusion of all patients with a depression, apathy was independently associated 
with male sex, worse global functioning and higher use of neuroleptics and benzodiazepines. 
 Therefore, the use of psychotropic medication should critically be evaluated when apathy is 
present ( Chapter 6).
Since neurodegeneration in Huntington’s disease occurs in various brain regions, including the 
hypothalamic areas, we finally investigated the function of the hypothalamic-pituitary-adrenal 
axis in relation to Huntington’s disease. A higher post-awakening salivary cortisol  concentration 
was found in presymptomatic mutation carriers compared to both symptomatic mutation 
 carriers and controls, indicating a hyperactivation of the hypothalamic-pituitary-adrenal axis in 







Dit proefschrift begint met een overzichtsartikel van oorspronkelijke onderzoek naar 
psycho pathologie bij bewezen mutatiedragers voor de ziekte van Huntington, waarbij 
 gestandaardiseerde instrumenten werden gebruikt (Hoofdstuk 2). Van de  neuropsychiatrische 
 symptomen komen depressieve stemming, apathie, angst, obsessieve en compulsieve 
 symptomen,  prikkelbaarheid en psychose voor. Veel van de studies hebben beperkingen zoals 
een kleine  onderzoekspopulatie en het ontbreken van een controlegroep, met bovendien een 
 uiteenlopende methodologie. 
Tussen mei 2004 en augustus 2006 hebben wij een grote cohortstudie opgezet om de 
 aanwezigheid en ernst van psychopathologie vast te stellen bij bewezen mutatiedragers voor 
de ziekte van Huntington in verschillende ziektestadia. Deze mutatiedragers werden vergeleken 
met eerstegraads niet-dragers en de algemene bevolking. 
Vijfentwintig procent van alle mutatiedragers heeft tenminste één formele psychiatrische 
 stoornis volgens de criteria van de Diagnostic Statistical Manual voor psychiatrische  stoornissen, 
versie IV (DSM-IV), met een significant verhoogde prevalentie van depressie, obsessieve- 
compulsieve stoornis en psychose. Eerstegraads niet-dragers hebben niet meer psychiatrische 
stoornissen dan de algemene bevolking, hoewel zij zijn opgegroeid in vergelijkbare, potentieel 
stressvolle omstandigheden (Hoofdstuk 3).
Naast een formele diagnostische classificatie volgens de criteria van de DSM-IV werd het vóór-
komen van gedragsproblemen ook vastgesteld met de Problem Behaviors Assessment (PBA), 
die is ontwikkeld voor de beoordeling van gedragsproblemen bij de ziekte van  Huntington. Na 
een factoranalyse van de PBA werden er drie factoren gevonden: apathie,  depressie en prikkel-
baarheid. Apathie was gerelateerd aan het ziektestadium, maar  depressie en prikkelbaarheid 
niet (Hoofdstuk 4). 
Het gebruik van algemene diagnostische criteria voor de beoordeling van psychopathologie bij 
de ziekte van Huntington is gecompliceerd wanneer co-morbide en overlappende somatische en 
cognitieve symptomen aanwezig zijn of als er sprake is van een verminderd ziektebesef.  Omdat 
de PBA en de gedragsschaal van de Unified Huntington’s Disease Rating Scale (UHDRS-b) ook de 
observatie van gedrag en informatie van verzorgers gebruiken, zijn deze  instrumenten geschikt 
voor de beoordeling van psychopathologie in gevorderde stadia van de ziekte van  Huntington 
(Hoofdstuk 5). 
Van de mutatiedragers hadden er negenenveertig (32%) apathie, terwijl geen van de  niet- dragers 
apathisch was. Na exclusie van alle depressieve patiënten, was apathie  onafhankelijk 
 geassocieerd met mannelijke geslacht, slechter algemeen functioneren en het gebruik van 
meer antipsychotica en benzodiazepines. Om deze reden moet het gebruik van psychotrope 
 medicatie kritisch worden beoordeeld wanneer apathie aanwezig is (Hoofdstuk 6). 
Omdat neurodegeneratie bij de ziekte van Huntington in verschillende hersengebieden 
 voorkomt, waaronder hypothalame gebieden, werd tenslotte de relatie tussen het  functioneren 
van de hypothalamus-hypofyse-bijnier-as en de ziekte van Huntington onderzocht. Bij pre-
symptomatische mutatiedragers werd een hogere cortisolconcentratie in het speeksel na het 
 ontwaken gevonden ten opzichte van zowel symptomatische mutatiedragers als controles, 
wat wijst op een mogelijke hyperactivatie van de hypothalamus-hypofyse-bijnier-as bij pre- 
symptomatische mutatiedragers (Hoofdstuk 7).
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(Beoordelingsschaal voor Probleemgedrag bij de Ziekte van Huntington)
Origineel:  D. Craufurd, J.C. Thompson, J.S. Snowden: Behavioral Changes in Huntington 
Disease (2001)
Vertaling: E.M. Kingma, R.C. van der Mast, R.A.C. Roos
Instructie
De beoordelingsschaal van probleemgedrag (PBA) bij de ziekte van Huntington is een  instrument 
voor het scoren van de aanwezigheid, frequentie en ernst van abnormaal gedrag bij  patiënten 
met de ziekte van Huntington. Het is bedoeld voor gebruik door getrainde psychiaters met 
 ervaring in het beoordelen van patiënten met neuropsychiatrische aandoeningen. Scores 
 moeten worden gebaseerd op informatie van (a) patiënt, (b) een goed ingelichte informant en 
(c) de observaties van de onderzoeker tijdens het onderzoek van de psychische functies van de 
patiënt. Probeer, als dat mogelijk is, ook de informant te interviewen zonder dat patiënt daar-
bij aanwezig is en voordat de scores ingevuld worden. Scoor, tenzij anders is aangegeven, het 
 gemiddelde gedrag van patiënt over de afgelopen 4 weken met behulp van de criteria die nader 
zijn gespecificeerd. Dit instrument is niet bedoeld om te gebruiken als vragenlijst.
Symptomen worden gescoord op frequentie en ernst met behulp van dezelfde 5-puntsschaal als 
in de Unified Huntington’s Disease Rating Scale. De hierna volgende richtlijnen zijn ontwikkeld 
om het gebruik ervan verder te verduidelijken en de inter-beoordelaars-betrouwbaarheid van 
het instrument te vergroten.
Instructies voor het invullen van de frequenstiescores
Frequentiescores zijn dezelfde als in de UHDRS behalve dat code 1 (zelden) wordt gedefinieerd 
als minder dan een keer per week optredend, en code 3 (herhaaldelijk) als ‘de meeste dagen 
optredend’. De frequentiescores worden dus consequent gebruikt voor frequentie in de zin van 
aantal dagen per week (duidelijk geschikt voor symptomen zoals slaapproblemen en  agressieve 
uitbarstingen), terwijl de duur van symptomen zoals piekeren of depressieve gedachten  expliciet 
is opgenomen in de ernstscores (die het, onvermijdelijk, toch al beïnvloedt).
Code 0 Nooit of bijna nooit
Code 1 (zelden) Minder dan een keer per week optredend
Code 2 (soms) Ten minste een keer per week optredend
Code 3 (herhaaldelijk) De meeste dagen van de week optredend
Code 4 (vaak) Bijna altijd
Instructies voor het invullen van de ernstscores
De gedetailleerde beschrijvingen hieronder zijn alle gebaseerd op dezelfde algemene  principes: 
de ernst wordt bepaald door de hoeveelheid leed die het veroorzaakt voor de patiënt of 
diens familie, de mate waarin het de dagelijkse routine verstoort, en de hoeveelheid tijd die 
het  symptoom in beslag neemt of de mate waarin het symptoom het denken van de patiënt 
 beheerst. Als algemene regel geldt:
Code 1 (twijfelachtig) Wordt gebruikt als de beoordelaar niet helemaal overtuigd is dat 
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Code 2 (licht) Symptoom is aanwezig, maar veroorzaakt geen ongemak. Symp- 
 toom is aanwezig, maar verstoort normale activiteiten niet.
 Symptoom is vluchtig of slechts af en toe aanwezig.
Code 3 (matig) Symptoom veroorzaakt aanmerkelijk ongemak.
 Symptoom verstoort duidelijk het dagelijks leven.
 Symptoom neemt een substantieel deel van de aandacht van 
 patiënt in beslag.
 
Code 4 (ernstig) Symptoom veroorzaakt ernstig of ondraaglijk leed.
 Symptoom maakt normaal leven onmogelijk.
 Symptoom is continu aanwezig en alle psychische activiteit van 




 1 Twijfelachtig of van weinig belang.
 2 Gedrukte stemming is met tussenpozen aanwezig, maar verstoort het dagelijks 
  functioneren niet.
 3 Patiënt is een groot gedeelte van de tijd somber en heeft geen plezier meer in wat  
  hij/zij gewoonlijk leuk vindt, maar kan soms nog met veel moeite in een betere  
  stemming komen.
 4 Patiënt voelt zich voortdurend diep ongelukkig.
2. Inslaapstoornis:
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Heeft maximaal één uur nodig om in slaap te vallen.
 3 Heeft tussen één en twee uur nodig om in slaap te vallen.
 4 Heeft meer dan twee uur nodig om in slaap te vallen.
3. Vroeg wakker worden:
 Houdt bij het scoren er rekening mee of patiënt eerder dan normaal gaat slapen en wat 
 de gebruikelijke tijd van wakker worden is.
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Wordt tot maximaal één uur eerder wakker dan gewoonlijk.
 3 Wordt tussen één en twee uur eerder wakker dan gewoonlijk.
 4 Wordt meer dan twee uur eerder wakker dan gewoonlijk.
4. Slaapt of is overdag slaperig:
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Slaperig gedurende enige tijd overdag, maar slaapt niet en het symptoom verstoort  
  het normale functioneren niet in belangrijke mate (één dutje wordt nog beschouwd  
  als normaal).
 3 Slaperig gedurende het grootste gedeelte van de dag, en slaapt overdag wat het  
  normale functioneren verstoort.
 4 Slaapt het grootste gedeelte van de dag.
5. Depressieve cognities:
 Laag gevoel van eigenwaarde, pessimistisch, zelfbeschuldigend zonder dat daarvoor een 
 reden is, zelfdevaluerend, heeft het idee tekort te schieten.
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Patiënt heeft de neiging alles van de zwarte kant te zien, maar het symptoom is niet  
  ernstig genoeg om dagelijkse activiteiten te verstoren.
 3 Depressieve cognities beïnvloeden het gedrag, maar patiënt kan daar nog steeds 
  afstand van nemen als dat nodig is (bijvoorbeeld in gezelschap).
 4 Depressieve cognities zijn constant aanwezig en het hele denken van de patiënt is  
  ervan doordrongen.
6. Angst:
 Gebruik dit onderdeel om de cognitieve aspecten van gepieker en angst te scoren.
 0 Afwezig.
 1 Twijfelachtig, onbestemd gevoel van je niet op je gemak voelen (scoor ook 1 als de  
  patiënt zich alleen zorgen maakt over de prognose van de ziekte van Huntington).
 2 Patiënt heeft met enige regelmaat last van gepieker en angst, maar het symptoom  
  is niet ernstig genoeg om aanmerkelijk ongemak te veroorzaken of dagelijkse 
  activiteiten te verstoren.
 3 Angst en/of ongerustheid is het grootste gedeelte van de tijd aanwezig, en heeft een 
  aanmerkelijke invloed op het gedrag van de patiënt (bijvoorbeeld: vermijdt plaatsen  
  die geassocieerd zijn met het uitlokken van angst).
 4 Angst is constant aanwezig en heeft een zeer grote invloed op de manier van leven  
  van patiënt (bv. agorafobie is dusdanig dat patiënt het huis niet meer kan verlaten  
  zonder begeleiding); regelmatige paniekaanvallen zijn ook voldoende reden om een  
  4 te scoren.
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 Dit onderdeel is bedoeld om niet alleen de fysiologische aspecten van angst weer te  
 geven, maar ook het gevoel van innerlijke spanning (gewoonlijk geassocieerd met 
 spanningshoofdpijn, pijnlijke schouders, en spierpijn) dat vaak voor lijkt te komen bij  
 patiënten met de ziekte van Huntington.
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Patiënt ervaart met tussenpozen gevoelens van spanning, maar het symptoom is niet
  ernstig genoeg om aanmerkelijk ongemak te veroorzaken of dagelijkse activiteiten te 
  verstoren.
 3 Patiënt kan het grootste gedeelte van de tijd niet ontspannen en ziet dit symptoom  
  als een oorzaak van aanmerkelijk ongemak.
 4 Patiënt is constant gespannen, kan zich helemaal niet ontspannen, heeft frequent  




 1 Twijfelachtig; scoor ook 1 als patiënt van plan is om zich te suïcideren als de ziekte  
  ernstiger zal zijn, maar daar troost van ondervindt als een manier om controle te  
  behouden over zijn/haar toekomst.
 2 Patiënt is soms erg pessimistisch met vluchtige suïcidale gedachten.
 3 Patiënt heeft indringende en kwellende gevoelens van hopeloosheid en frequente  
  suïcidale gedachten, maar heeft daar nog niet naar gehandeld.
 4 Patiënt heeft een suïcidepoging gedaan of heeft daar de voorbereidingen toe 
  getroffen zoals het sparen van pillen en het plannen van manieren om ontdekking te 
  voorkomen als het zover zou zijn.
9. Energieverlies:
 Bij het scoren van dit onderdeel moet rekening gehouden worden met zowel de 
 premorbide toestand van de patiënt als die van een “normaal” persoon.
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Patiënt klaagt dat hij zich na normale activiteiten uitgeput voelt, maar dit heeft geen 
  merkbaar effect op de hoeveelheid activiteiten die hij onderneemt.
 3 Er is sprake van een duidelijke vermindering in de mate van activiteit van de patiënt.




 1 Twijfelachtig of van weinig belang.
 2 Patiënt en/of verzorger heeft een verandering bemerkt  (bijv. verzorgt uiterlijk niet  
  meer in dezelfde mate of neemt de moeite niet meer om zich op te maken) maar die 
  blijft binnen sociaal-acceptabele grenzen.
 3 De zelfverzorging van de patiënt is verslechterd tot onder sociaal-acceptabele  
  grenzen (bijv. verzorger moet patiënt soms aansporen om zich te scheren of schone  
  kleren aan te trekken).
 4 Patiënt wast of doucht zich niet meer tenzij hij/zij daartoe wordt aangespoord.
 
11. Verlies van eetlust:
 Beoordeel dit onderdeel en het volgende vooral in vergelijking met de premorbide 
 toestand van de patiënt.
 0 Geen verandering, symptoom afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Patiënt en/of verzorger heeft een vermindering van eetlust bemerkt, maar niet 
  voldoende om enigermate zorgwekkend te zijn.
 3 Patiënt eet duidelijk minder dan voorheen.
 4 Het verlies van eetlust van de patiënt is zo ernstig dat de verzorger moet zorgen voor 
  een adequate voedselinname van de patiënt.
12. Toename van eetlust:
 0 Geen verandering, symptoom afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Patiënt en/of verzorger heeft een toename in eetlust bemerkt, maar niet voldoende 
  om enigermate zorgwekkend te zijn.
 3 Patiënt eet duidelijk meer dan voorheen.
 4 De toename in eetlust van de patiënt is zo ernstig dat de verzorger overmatige 
  voedselinname moet beperken.
13. Schrokken van voedsel:
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Patiënt heeft de neiging om te snel te eten, maar niet in die mate dat het de 
  verzorger zorgen baart.
 3 Verzorger moet patiënt soms berispen voor te snel eten.
 4 Patiënt slikt het eten door zonder te kauwen en propt het eten in zijn mond voor de  
  vorige hap is doorgeslikt.
14. Verandering in voedselvoorkeur:
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Duidelijke verandering in voedselvoorkeur (bijv. patiënt heeft een voorliefde voor  
  zoet eten ontwikkeld), maar niet in die mate dat het de verzorger zorgen baart.
 3 Grote verandering in voedselvoorkeur wat resulteert in een ongepast/ongezond 
  dieet.
 4 Patiënt beperkt zijn dieet tot een paar hoogst ongepaste etenswaren (bv. wil niets  
  anders eten dan chocoladebonbons).
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 1 Twijfelachtig of van weinig belang.
 2 Moet af en toe aangespoord worden om de gewone dagelijkse taken te doen.
 3 Heeft regelmatig/bijna altijd aansporing nodig om gewone dagelijkse taken te doen.
 4 Doet niets, zelfs niet bij herhaaldelijke aansporing.
16. Onvermogen om dagelijkse taken af te maken:
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Slaagt er af en toe niet in om de gewone dagelijkse taken af te maken.
 3 Slaagt er regelmatig niet/bijna nooit in om gewone dagelijkse taken af te maken.
 4 Doet niets meer.
17. Kwaliteit van werk:
 Deze scores refereren aan dagelijkse routine taken (bv. huishoudelijk werk of 
 eenvoudige klusjes) waarvan van iedereen verwacht mag worden dat die dat kan. Scoor 
 geen beperkingen van beroepsmatig werk.
 0 Geen beperking.
 1 Twijfelachtig of van weinig belang.
 2 Er is sprake van een duidelijke verandering, maar de kwaliteit van het werk is nog  
  steeds binnen normale grenzen.
 3 Er is sprake van een aanmerkelijke verandering en de kwaliteit van het werk is nu  
  beslist beneden peil.
 4 De taak komt niet af, of het resultaat is geheel onbruikbaar, of patiënt doet helemaal 
  niets meer.
18. Oordeelsvermogen en zelfkritisch vermogen:
 0 Geen beperking.
 1 Twijfelachtig of van weinig belang.
 2 Patiënt is soms impulsief, denkt niet na over de gevolgen van acties, maakt 
  inschattingsfouten, maar zonder dat die een belangrijke invloed hebben op het leven 
  van patiënt.
 3 Patiënt schat de uitkomst van acties of beslissingen regelmatig verkeerd in wat soms 
  leidt tot praktische problemen voor de patiënt zelf of zijn/haar verzorgers.
 4 Patiënt is niet in staat om op de uitkomsten van acties of beslissingen te anticiperen 
  wat ernstige sociale of praktische gevolgen heeft; heeft constante begeleiding nodig 
  voor zijn/haar eigen bescherming.
19. Affectvervlakking:
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Er is sprake van een merkbare vermindering in emotionele gevoeligheid.
 3 Afstomping van het affect is ernstig genoeg om enig ongemak bij verzorgers, familie  
  of vrienden te veroorzaken.
 4 Volslagen afwezigheid van interactie met anderen; patiënt vertoont alleen nog 
  emotionele reacties als het hemzelf betreft.
20. Egocentrisch, veeleisend:
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Patiënt is merkbaar meer egocentrisch dan voor zijn/haar ziekte, maar dit 
  veroorzaakt geen praktische problemen voor de verzorger of familie.
 3 Patiënt vertoont zelfzuchtig en /of veeleisend gedrag op verschillende gebieden van  
  het dagelijks leven; veroorzaakt praktische problemen of aanmerkelijk ongemak voor 
  andere leden van het gezin.
 4 Zelfzuchtig en/of veeleisend gedrag is constant aanwezig en onverdraaglijk voor 
  verzorger of andere gezinsleden, wat het risico creëert dat patiënt zal worden 
  afgewezen.
21. Inflexibel, niet coöperatief:
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Patiënt is merkbaar minder flexibel of coöperatief dan voor zijn/haar ziekte, maar dit 
  heeft geen aanmerkelijke praktische problemen voor de verzorger of familie 
  veroorzaakt.
 3 De tegenzin van patiënt om van de routine af te wijken of de weigering om zich te  
  schikken naar redelijke wensen van andere gezinsleden veroorzaakt aanmerkelijke  
  praktische problemen voor verzorgers.
 4 Patiënt kan niet omgaan met afwijkingen van de vaste dagelijkse routine.
22. Wilszwakte:
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Patiënt is merkbaar meer passief dan voor zijn/haar ziekte, maar dit veroorzaakt  
  geen praktische problemen.
 3 Gebrek aan wilsuiting is zodanig dat patiënt kwetsbaar is voor uitbuiting.
 4 Patiënt laat geen eigen wil zien.
23. Obsessionele ideeën, gedachten, angsten, overpeinzingen, beelden:
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Er zijn af en toe obsessionele gedachten, maar deze verstoren het dagelijks leven niet 
  en veroorzaken voor de patiënt geen aanmerkelijk ongemak.
 3 Er is sprake van obsessionele symptomen zodanig dat deze het dagelijks leven 
  verstoren of aanmerkelijk ongemak veroorzaken voor de patiënt.
 4 De obsessionele verschijnselen beheersen bijna het gehele denken van patiënt en  
  veroorzaken ernstige praktische problemen of leed.
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 1 Twijfelachtig of van weinig belang.
 2 Er is sprake van dwangmatige neigingen maar patiënt kan deze gewoonlijk weerstaan 
  en het symptoom verstoort het dagelijks leven niet en veroorzaakt geen 
  aanmerkelijk ongemak.
 3 Dwangmatig gedrag komt regelmatig voor en patiënt is niet in staat om dit te 
  weerstaan; de dwanghandelingen verstoren het dagelijks leven of veroorzaken bij de 
  patiënt aanmerkelijk ongemak.
 4 Dwanghandelingen nemen een groot gedeelte van de tijd in beslag en veroorzaken 
  serieuze praktische problemen of leed.
 
25. Pathologische preoccupaties:
 Dit zijn vaste ideeën of thema’s die de aandacht van de patiënt overmatig of op de 
 verkeerde momenten in beslag nemen (bijv voortdurende preoccupatie met de 
 behoefte om naar de wc te gaan wat het denken en het gesprek domineert) zoals vaak  
 voorkomt bij patiënten met de ziekte van Huntington. Patiënt beschouwt deze niet als  
 ongepast, noch ervaart hij/zij een drang om deze te weerstaan, en ook zijn ze niet 
 noodzakelijkerwijs geassocieerd met subjectieve angst of ongerustheid; ze 
 vertegenwoordigen waarschijnlijk eerder een aandachtsstoornis dan een echt 
 obsessioneel verschijnsel.
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Er is sprake van abnormale preoccupaties, maar deze verstoren het dagelijks leven  
  niet en veroorzaken voor patiënt of verzorgers geen aanmerkelijk ongemak.
 3 De abnormale preoccupaties nemen een aanmerkelijk deel van de aandacht van  
  patiënt in beslag en veroorzaken aanmerkelijk ongemak voor patiënt of praktische  
  problemen voor verzorgers.
 4 De abnormale preoccupaties nemen het grootste gedeelte van de aandacht van 
  patiënt in beslag en veroorzaken zeer grote problemen en leed voor patiënt en 
  verzorgers.
26. Prikkelbaarheid:
 Op dit item wordt het gemak gescoord waarmee patiënt kwaad wordt; niet de mate  
 waarin patiënt de zelfbeheersing verliest als hij/zij eenmaal boos is (het laatste wordt  
 gescoord in de volgende twee items).
 0 Niet prikkelbaarder dan een normaal persoon.
 1 Twijfelachtig of van weinig belang; binnen de grenzen van het normale maar sneller  
  geprikkeld dan vroeger. 
 2 Patiënt is beslist prikkelbaarder dan redelijk is, maar niet in die mate dat het 
  aanmerkelijke problemen of ongemakvoor andere gezinsleden veroorzaakt.
 3 Patiënt is erg prikkelbaar en wordt kwaad over onbelangrijke zaken; gezinsleden  
  moeten voorzichtig zijn met wat zij zeggen en doen om problemen te voorkomen.
 4 Patiënt is voortdurend erg prikkelbaar en wordt kwaad zonder dat daar een 
  duidelijke reden voor is; met hem/haar samenleven is als lopen op eieren.
27. Opvliegendheid, verbale uitvallen:
 Op dit item (en het volgende) wordt het gebrek aan zelfbeheersing gescoord als patiënt 
 kwaad is. De twee items (verbale uitvallen en gewelddadig gedrag) worden op de 
 UHDRS schaal als één item gescoord; gebruik de hoogste score.
 0 Normaal.
 1 Twijfelachtig of van weinig belang; binnen de grenzen van het normale, maar erger  
  dan hij/zij gewoonlijk was.
 2 Er is af en toe sprake van verbale uitbarstingen die buiten sociaal-acceptabele 
  grenzen zijn, maar die geen aanmerkelijke problemen of ongemak veroorzaken voor  
  de andere gezinsleden.
 3 De driftbuien zijn ernstig genoeg om aanmerkelijk ongemak te veroorzaken voor de  
  andere gezinsleden en/of praktische problemen bij het verzorgen van patiënt.
 4 De patiënt heeft zulke ernstige driftbuien dat de relatie met verzorgers bedreigd  
  wordt. Daarmee loopt patiënt het risico dat hij/zij afgewezen zou kunnen worden.
28. Dreigend gedrag, geweld:
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Geweld gericht op objecten (bijv schopt tegen meubels, smijt met deuren).
 3 Er is sprake van bedreiging met geweld jegens personen, of meer extreme schade  
  aan objecten wat een gerede angst veroorzaakt bij de overige gezinsleden voor tegen 
  personen gericht geweld.
 4 Er is sprake van daadwerkelijke lichamelijk geweld, of bedreigingen met een dodelijk 




 1 Twijfelachtig of van weinig belang.
 2 Er zijn nu en dan hypochondrische zorgen die het gedrag van patiënt niet 
  beïnvloeden.
 3 Er is sprake van hypochondrische preoccupaties die het grootste gedeelte van de tijd 
  aanwezig zijn en een aanmerkelijke invloed op het gedrag van patiënt hebben 
  (bijv frequente bezoeken aan de dokter).
 4 De hypochondrische preoccupaties nemen de aandacht van patiënt in beslag en 
  verstoren de dagelijkse routine aanzienlijk.
30. Verlies van libido:
 Scores op dit onderdeel weerspiegelen voornamelijk een verandering van de 
 premorbide toestand van patiënt.
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
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 2 Patiënt is minder geïnteresseerd in seks dan voordat de ziekte begon.
 3 Er is sprake van een aanmerkelijk verlies van seksueel verlangen en activiteit, 
  wat  problemen kan veroorzaken in de relatie met echtgenoot/partner.
 4 Patiënt heeft geen enkel seksueel verlangen of seksuele activiteiten meer.
31. Seksuele ontremming:
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Patiënt is merkbaar meer ontremd wat betreft seksuele zaken dan voor de ziekte,  
  maar het gedrag blijft binnen sociaal acceptabele grenzen.
 3 Er is sprake van sociaal onacceptabel ontremd seksueel gedrag.
 4 Het seksuele ontremde gedrag van patiënt zou hem/haar in de problemen kunnen  
  brengen met politie, of zou afwijzing door partner, familie of andere verzorgers 
  kunnen veroorzaken.
32. Seksueel veeleisend gedrag:
 Dit onderdeel wordt gebruikt om veranderingen in/afwijkingen van seksueel gedrag te  
 scoren binnen de context van de relaties van patiënt in plaats van de openlijke 
 manifestaties van seksualiteit. Tenzij het gedrag van patiënt buitengewoon abnormaal  
 is, is het waarschijnlijk dat de scores vooral veranderingen ten opzichte van de 
 premorbide gedragspatronen van de patiënt zullen weerspiegelen.
 0 Afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Patiënt is merkbaar seksueel actiever dan voor zijn/haar ziekte, maar het gedrag blijft 
  voor de partner binnen acceptabele grenzen.
 3 Patiënt stelt buitensporig frequente, grove, ongevoelige of agressieve seksuele eisen 
  die voor de partner onacceptabel zijn.
 4 Er is sprake van zodanig veeleisend of pervers seksueel gedrag dat het zeer veel leed 
  veroorzaakt voor de partner en de relatie kapot dreigt te maken.
33. Wanen:
 0 Symptoom afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Er is af en toe sprake van overwaardige ideeën (géén wanen) maar deze beïnvloeden 
  het gedrag van patiënt niet.
 3 De overwaardige ideeën zijn een groot gedeelte van de tijd aanwezig ofschoon 
  patiënt (met moeite) ervan overtuigd kan worden dat hij/zij het mis heeft; patiënt  
  gedraagt zich alsof deze ideeën echt zouden zijn.
 4 Er is sprake van wanen: niet te corrigeren onjuiste denkbeelden, die niet worden 
  gedeeld door andere leden van de sociale en culturele groep van patiënt en die min  
  of meer continu aanwezig zijn geweest gedurende tenminste 7 dagen.
34. Jaloezie:
 0 Symptoom afwezig.
 1 Twijfelachtig of van weinig belang; scoor ook 1 als er een duidelijke basis is voor de  
  jaloezie van patiënt.
 2 Patiënt lijkt jaloers, vindt het moeilijk om echtgenoot/partner alleen uit te laten  
  gaan, en koestert wrok als hij/zij dat wel doet.
 3 Patiënt is openlijk jaloers, beschuldigt zijn/haar partner onterecht van ontrouw wat  
  aanzienlijke ruzies veroorzaakt, en aanmerkelijk ongemak voor de partner.
 4 Patiënt is er onwankelbaar van overtuigd (onterecht) dat zijn/haar partner hem/haar 
  ontrouw is en gedraagt zich om deze reden onredelijk (bijv volgt partner, huurt 
  detectives etc.).
35. Hallucinaties:
 0 Symptoom afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Patiënt meldt (desgevraagd) dat hij/zij hallucinaties ervaart, maar deze lijken geen 
  ongemak te veroorzaken of het gedrag van patiënt te beïnvloeden.
 3 Er is sprake van hallucinaties die het gedrag van patiënt beïnvloeden (bijv zoeken  
  naar de bron van verborgen stemmen of watten in de oren stoppen), maar geen  
  verder leed lijken te veroorzaken.
 4 Patiënt wordt duidelijk gekweld door hallucinaties en is ermee gepreoccupeerd.
36. Gedrag geassocieerd met verstoorde temperatuurregulatie:
 0 Symptoom afwezig.
 1 Twijfelachtig of van weinig belang.
 2 Patiënt heeft een verstoring van de temperatuurregulatie bemerkt of heeft gemerkt 
  dat hij/zij overvloedig zweet, maar dit heeft geen significant leed veroorzaakt, noch 
  heeft het diens gedrag beïnvloed.
 3 Patiënt wordt gekweld door verstoorde temperatuurregulatie en onderneemt 
  acties (bijv het openen van ramen als het koud is) die lastig zijn voor andere 
  gezinsleden.
 4 Het gedrag door de verstoorde temperatuurregulatie veroorzaakt aanmerkelijke 
  praktische problemen, (bv. staat erop dat alle ramen de hele nacht open blijven 
  ondanks veiligheidsrisico’s). 
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Unified Huntington’s Disease Rating Scale (UHDRS): behavioral section
(Gedragsproblemen)
© 1999 Huntington Study Group.™
Instructie
Beoordeel de frequentie en de ernst van het gedrag. Deze beoordeling moet op alle beschikbare 
informatie worden gebaseerd, gebruik makend van de indruk van de clinicus, het rapport over 




0 = nooit of bijna nooit
1 = zelden, minder dan eenmaal per week
2 = soms, minstens eenmaal per week
3 = regelmatig, meerdere keren per week
4 = erg vaak, bijna altijd
Ernst:
0 = geen stemmingsstoornissen
1 = twijfelachtig
2 = licht, reageert op geruststelling
3 = matig depressief, geeft uiting van lijden




0 = nooit of bijna nooit
1 = zelden, minder dan eenmaal per week
2 = soms, minstens eenmaal per week
3 = regelmatig, meerdere keren per week
4 = erg vaak, bijna altijd
Ernst:
0 = geen aanwijzingen
1 = twijfelachtig
2 = licht, duidelijk aanwezig




0 = nooit of bijna nooit
1 = zelden, minder dan eenmaal per week
2 = soms, minstens eenmaal per week
3 = regelmatig, meerdere keren per week
4 = erg vaak, bijna altijd
Ernst:
0 = geen aanwijzingen
1 = twijfelachtig
2 = licht, reageert op geruststelling
3 = matig, beïnvloedt dagelijks functioneren
4 = ernstig, belemmert activiteiten
 4. Suïcidale gedachten:
Frequentie:
0 = geen gedachten over suïcide of 
zelfbeschadiging
1 = zelden suïcidegedachten, minder dan 
eenmaal per maand
2 = soms gedachten over suïcide, minstens 
eenmaal per week
3 = regelmatig gedachten over suïcide, 
minstens eenmaal per week
4 = vaak gedachten over suïcide, soms dagen 
of weken achter elkaar
Ernst:
0 = geen suïcidale gedachten
1 = op dit moment geen gedachten, 
maar praat over suïcide als mogelijkheid
2 = vluchtige gedachten over suïcide
3 = serieus suïcide overwogen, maar 
heeft geen plannen
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5. Opvliegend of agressief gedrag:
Frequentie:
0 = nooit of bijna nooit
1 = zelden, minder dan eenmaal per maand
2 = soms, minstens eenmaal per maand
3 = regelmatig, minstens eens per week
4 = erg vaak, elke dag
Ernst:
0 = gedrag is goed onder controle
1 = verbale bedreigingen of intimiderend 
gedrag
2 = duidelijk fysiek of verbaal dreigend gedrag
3 = duidelijk fysieke dreiging (matige 
agressie), stoten, schuiven, verbale 
uitbarstingen
4 = duidelijke fysieke dreiging (ernstige 
agressie), slaan, of duidelijke intentie om
iemand pijn te doen
6. Prikkelbaarheid:
Frequentie:
0 = nooit of bijna nooit
1 = zelden, minder dan eenmaal per week
2 = soms, minstens eenmaal per week
3 = regelmatig, meerdere keren per week
4 = erg vaak, bijna altijd
Ernst:
0 = gedrag is goed onder controle
1 = twijfelachtig
2 = duidelijk, maar licht
3 = matig, anderen veranderen hun gedrag om 
te vermijden dat patiënt geïrriteerd wordt
4 = ernstige irritatie
7. Perseverend/obsessioneel denken:
Frequentie:
0 = nooit of bijna nooit
1 = zelden, minder dan eenmaal per week
2 = soms, minstens eenmaal per week
3 = regelmatig, meerdere keren per week
4 = erg vaak, bijna altijd
Ernst:
0 = denken is altijd flexibel
1 = twijfelachtig
2 = blijft hangen op bepaalde ideeën, maar 
deze kunnen wel worden gewijzigd
3 = matig, blijft hangen op bepaalde ideeën, 
moeilijk om deze bij te sturen
4 = ernstig, blijft hangen op bepaalde ideeën, 
laat zich niet bijsturen 
8. Compulsief gedrag:
Frequentie:
0 = nooit of bijna nooit
1 = zelden, minder dan eenmaal per week
2 = soms, minstens eenmaal per week
3 = regelmatig, meerdere keren per week
4 = erg vaak, bijna altijd
Ernst:
0 = gedrag is goed onder controle
1 = twijfelachtig, heeft lichte impulsen, han-
delt daar nog niet naar
2 = licht, heeft impulsen, handelt ernaar, maar 
kan stoppen
3 = matig, heeft impulsen, handelt ernaar, en 
kan het soms niet stoppen





0 = geen aanwijzingen
1 = zelden, minder dan eenmaal per maand
2 = soms, minstens eenmaal per maand
3 = regelmatig, minstens eenmaal per week
4 = erg vaak, soms dagen achtereen
Ernst:
0 = geen aanwijzingen
1 = heeft waanachtige denkbeelden, weet niet 
zeker of het waar is
2 = overtuigd van idee(ën), maar accepteert 
dat het niet waar is
3 = volledig overtuigd van idee(ën)
4 = volledig overtuigd van idee(ën), gedrag 
wordt er door bepaald
10. Hallucinaties:
Frequentie:
0 = geen aanwijzingen of hallucinaties
1 = zelden, minder dan eenmaal per maand
2 = soms, minstens eenmaal per maand
3 = regelmatig, minstens eenmaal per week
4 = erg vaak, soms dagen achtereen
Ernst:
0 = geen aanwijzingen
1 = heeft hallucinaties, maar twijfelt of 
ze echt zijn
2 = overtuigd van de realiteit ervan, 
maar houdt er rekening mee dat ze onjuist zijn
3 = volledig overtuigd dat ze echt zijn, 
maar handelt er niet naar
4 = ernstig, heeft levendige hallucinaties, 
overtuigd van het feit dat ze waar zijn en ze 




1 = zelden, minder dan eenmaal per week
2 = soms, minstens eenmaal per week
3 = regelmatig, meerdere keren per week
4 = erg vaak, bijna altijd
Ernst:
0 = geen aanwijzingen
1 = twijfelachtig
2 = lichte apathie, initieert geen gesprek of ac-
tiviteit, maar reageert wel
3 = matige apathie, reageer soms op initia-
tieven om betrokken te worden bij gesprek/
activiteit
4 = ernstige apathie, over het algemeen niet 
responsief op pogingen om betrokken te wor-
den bij activiteiten of gesprekken
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Instructie
Lees de vragen voor en laat de deelnemer het antwoord kiezen. De deelnemer mag de partner 
of verzorger om raad vragen en de beoordelaar moet ook het oordeel van de partner/verzorger 
en zijn/haar eigen indruk laten meewegen. Omdat het een semi-gestructureerd interview is, 
kan bij onduidelijkheden een toelichting gegeven worden of om verheldering gevraagd worden.
Mogelijke antwoorden:
- in het geheel niet aanwezig
- weinig aanwezig
- aanwezig 
- sterk aanwezig 
1. Heeft u belangstelling om dingen te leren? 
2. Heeft iets uw interesse? 
3. Is het nodig dat een ander u zegt wat u op een dag moet doen?
4. Bent u bezorgd om uw gezondheid?
5. Maakt het u allemaal niet uit wat er gebeurt?
6. Steekt u veel energie in de dingen die u doet?
7. Bent u altijd op zoek naar dingen die u kunt doen?
8. Heeft u plannen en stelt u zichzelf doelen voor de toekomst?
9. Bent u gemotiveerd?
10. Heeft u voldoende energie voor uw dagelijkse bezigheden?
11. Bent u niet meer betrokken bij veel dingen?
12. Hebt u een aanzet nodig om ergens aan te beginnen?
13. Voelt u zich niet opgewekt of verdrietig, maar iets daartussenin?
14. Zou u zichzelf apathisch noemen?
Berekening
Vragen 1, 2, 4, 6-10 : 
in het geheel niet aanwezig = 3; weinig aanwezig = 2; aanwezig = 1; sterk aanwezig = 0.
Vragen 3, 5, 11-14: 
in het geheel niet aanwezig = 0; weinig aanwezig = 1; aanwezig = 2; sterk aanwezig = 4.
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